

JOSEPH R. CALABRESE, M.D.

- Curriculum Vitae -

(8/21/09 revision)

OFFICE ADDRESS:

Mood Disorders Program
10524 Euclid Avenue, 12th floor,
Mail Stop WLK-5080
Cleveland, Ohio 44106

Telephone: 216/844-2865
Home: 216/752-9569
Mobile: 216/533-7960
FAX 216/844-2875
E-mail: Joseph.Calabrese@UHhospitals.org
Mood Disorders Program website: <http://case.edu/mdp>

DATE & PLACE OF BIRTH:

February 7, 1953
Cleveland, Ohio

EDUCATION:

9/72 – 5/76 B.S. Xavier University
(major in biology, summa cum laude)

7/76 – 6/80 M.D. Ohio State University College of Medicine
(degree awarded with Honors in Psychiatry)

7/80 – 6/81 Resident in Internal Medicine
Cleveland Clinic Foundation
Cleveland, Ohio

7/81 – 6/84 Resident in Psychiatry
Cleveland Clinic Foundation
Cleveland, Ohio

7/82 - 6/84 Chief Resident
Department of Psychiatry
Cleveland Clinic Foundation
Cleveland, Ohio

7/84 – 6/86 Research Fellowship, Intramural Program
Section, Clin. Neuroendocrinology, Director, Phillip Gold,
Biological Psychiatry Branch, Director, Robert Post, M.D.
National Institute of Mental Health
Bethesda, Maryland

PROFESSIONAL EXPERIENCE:

5/07 'Bipolar Disorders Research Chair' awarded. To be renamed the "Joseph R. Calabrese Bipolar Disorders Research Chair" upon retirement or death, which ever comes first.

7/03 – Present Co-Director, Bipolar Disorders Interventions and Services Research Center

11/89 - Present Director, Mood Disorders Program
Department of Psychiatry
University Hospitals of Cleveland
Cleveland, Ohio

1/01 – 10/07 Director, Division of Ambulatory Care
Department of Psychiatry
University Hospitals of Cleveland
Cleveland, Ohio

7/05 Cleveland Clinic Lerner College of Medicine Clinical Research Summer Program Preceptor

5/96 Professor of Psychiatry with tenure
Case University School of Medicine
Cleveland, Ohio

9/96 – 9/07 Co-Director, Stanley Medical Research Institute
Bipolar Dis. Early Intervention Clinical Research Center
Case University School of Medicine
Cleveland, Ohio

9/94 – 9/00 Vice Chairman, Clinical Affairs
Department of Psychiatry
University Hospitals of Cleveland
Cleveland, Ohio

5/97 – 5/98 Associate Medical Director for Behavioral Health
QualChoice Health Plan, Inc.
Cleveland, Ohio

12/94 – 5/97 President & Chief Executive Officer
University Behavioral Health Care, Inc.
Cleveland, Ohio

5/89 – 5/96 Associate Professor of Psychiatry
Case University School of Medicine
Cleveland, Ohio

12/89 – 1/95
Medical Director, Adult Inpatient Unit
University Hospitals of Cleveland
Cleveland, Ohio

7/86 – 11/89
Head, Manic Depressive Clinic
Department of Psychiatry
Cleveland Clinic Foundation

COMMUNITY SERVICE:

1/06 – ongoing
Member, OHIO CARES Committee meeting, Ohio National
Guard
- Member, Sub-Committee on Quality Improvement, Tricare
Healthcare for the Reserve Component
- Chair, Provide Issues Committee

1/06 – 3/06
NARSAD Fund Development, Sarasota and Palm Beach,
Florida

11/02 – Present
Medical Advisor, Ohio Depression and Bipolar Support
Alliance (DBSA)

6/02 – Present
External Advisor to Canadian Consortium on Bipolar
Disorder

9/00 – Present
Member, Chapter Professional Advisors Committee, DBSA

1/97 - 2005
Medical Advisor, Alliance Mentally Ill of Metro Cleveland
National Alliance for the Mentally Ill
Cleveland, Ohio

9/92 - Present
Member, National Scientific Advisory Board, DBSA
Chicago, Illinois

3/4 – Present
Member, Executive Committee, Scientific Advisory Board,
DBSA

9/92 - 2005
Medical Advisor, Alliance for the Mentally Ill
of Cuyahoga County
National Alliance for the Mentally Ill
Cleveland, Ohio

1/87 - Present
Professional Advisor, Cleveland Chapter, DBSA
Cleveland, Ohio

SCIENTIFIC REVIEW OF RESEARCH APPLICATIONS:

Ad Hoc Reviewer for the National Institute of Mental Health, including:

1. Intramural reviews:
2. Extramural reviews:
 - a. Ad hoc Intervention and Services submissions
 - b. Chairperson, ASCEND Special Emphasis Panel/Scientific Review Group ERB-W(04) 2005 and 2006.
 - c. Ad hoc P20s and P30s submissions
 - d. Loan Repayment Program submissions in 2002 and 2004

Ad Hoc Reviewer Canadian Institutes of Health Research

Ad Hoc Reviewer Medical Research Council of the United Kingdom 2000-2007

Ad Hoc Stanley Medical Research Institute 1999-2005

Ad Hoc Reviewer for The Netherlands Organization for Health Research and Development (ZONMW)

Ad Hoc Reviewer for VA Cooperative Studies Genetics Subcommittee

COMMITTEE INVOLVEMENT:

| | |
|----------------|---|
| 8/06 – present | Member, Dean’s Research Advisory Board, Case Western Reserve University School of Medicine Research Institute |
| 2008 | Member, World Federation of Societies of Biological Psychiatry Guidelines for the Biological Treatment of Bipolar Disorder on the Treatment of Mania Task Force |
| 2004 – 2009 | Member, Committee on Education and Training America College of Neuropsychopharmacology - Chair, Sub-Committee on Expanding ACNP Education |
| 6/03 – 6/06 | Member, Committee on Appointments, Promotions, and Tenure, Case Western Reserve School of Medicine |
| 6/05 – 6/06 | Co-Chair, Committee on Appointments, Promotions, and Tenure, Case Western Reserve School of Medicine |
| 11/11/03 | Depression and Bipolar Support Alliance Consensus Conference of Dual Diagnosis Mood Disorders, Washington D.C. |
| 6/92 - Present | Member, Executive Committee Department of Psychiatry University Hospitals of Cleveland |

| | |
|----------------|---|
| 6/92 - Present | Member, Pharmacy and Therapeutics Committee University Hospitals of Cleveland |
| 5/05-7/05 | Ad Hoc P & T Committee on SSRIs on the Formulary University Hospitals Health System |
| 6/97 - Present | Member, Board of Trustees Clinical Neuroscience Research Foundation Department of Psychiatry |
| 6/94 - Present | Member, Board of Trustees University Psychiatrists of Cleveland, Inc. Department of Psychiatry Practice Plan |
| 1/02 – 12/02 | World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorder |
| 5/00 – 3/01 | Behavioral Health Peer Review Committee QualChoice Health Plan, Inc University Hospitals Health System |
| 7/00 – 7/01 | Impaired Physicians/Provider Committee University Hospitals of Cleveland |
| 5/95 – 3/01 | Clinical Quality Improvement Committee QualChoice Health Plan, Inc. University Hospitals Health System |
| 5/98 – 3/01 | Credentialing Committee QualChoice Health Plan, Inc. University Hospitals Health System |
| 6/98 - 9/00 | Search Committee for the Chairman Department of Psychiatry Case Western Reserve University School of Medicine |
| 3/96 – 9/98 | Managed Care Contracting Committee University Faculty Practice Association Case Western Reserve University University Hospitals of Cleveland |
| 5/94 – 7/98 | Medical Advisory Council QualChoice Health Plan, Inc. University Hospitals Health System |
| 1/90 – 7/92 | Chairman, Electroconvulsive Therapy Committee |

Department of Psychiatry
University Hospitals of Cleveland

4/90 – 4/91

Depression Panel, Council on Scientific Affairs
American Medical Association
Chicago, Illinois

1/90 – 3/93

Education Committee
Department of Psychiatry
University Hospitals of Cleveland

7/89 – 9/97

Examiner, American of Psychiatry and Neurology
Deerfield, Illinois

7/86 – 11/89

Human Research Committee, CNS,
Cleveland Clinic Foundation

7/86 – 11/89

Education Committee
Department of Psychiatry
Cleveland Clinic Foundation

HONORS & AWARDS:

5/08

2008 Gerald L. Klerman Lifetime Achievement Award, given annually by National Depression and Bipolar Support Alliance in recognition for a sustained record of outstanding lifetime scientific contributions, including service to the research community, contributions to training and mentoring young researchers, and advocacy for people living with mood disorders (including disadvantaged and underserved populations).

5/07

Awarded the **Bipolar Disorders Research Chair** whose name will be changed to the Joseph R. Calabrese, MD Bipolar Disorder Research Chair upon Dr. Calabrese's retirement or death.

5/06

'Ellis Island Medal of Honor' awarded annually by the National Ethnic Coalition of Organizations to a group of distinguished Americans citizens who are internationally recognized for professional service to humanity, who also have a special commitment to preserving ancestral values and building bridges between ethnic and racial groups.

10/04

NARSAD Lifetime Achievement Award for Psychiatric Research: "The Nola Maddox Falcone Prize for Affective Disorders (formerly the Selo Prize and the Lieber Prize)".

Awarded to outstanding scientists carrying out work on the causes, pathophysiology, treatment, or prevention of affective disorders

5/03 **'Dorothea Dix Humanitarian'** of the Year for work done in dual diagnosis bipolar disorder, Depression and Bipolar Support Alliance, Toledo, Ohio.

6/93 **Annual Staff Teacher of the Year**, Department of Psychiatry, CWRU School of Medicine, University Hospitals of Cleveland.

9/91 **National Young Investigator Research Award**, National Depressive and Manic Depressive Association (now known as the Depression and Bipolar Support Alliance)

6/89 **Annual Staff Teacher of the Year Award**, Department of Psychiatry, Cleveland Clinic Foundation

6/88 **Annual Staff Teacher of the Year Award**, Department of Psychiatry, Cleveland Clinic Foundation

6/84 **Richard M. Steinhilber, M.D. Resident Research Award**, Department of Psychiatry, Cleveland Clinic Foundation

6/80 Award for outstanding performance in psychiatry, Ohio State University College of Medicine

7/74 **Northeast Ohio Heart Association Medical Student Research Award**, Cleveland Clinic Foundation

6/73 **Northeast Ohio Heart Association Medical Student Research Award**, Cleveland Clinic Foundation

BOARD CERTIFICATION: Diplomat, Am. Board of Psychiatry and Neurology, 1989

AFFILIATIONS:
American College of Neuropsychopharmacology
- Fellow Status achieved 2007
American Psychiatric Association (Fellow)
American Medical Association
European College of Neuropsychopharmacology
International Society for Bipolar Disorders
International Society of Clinical Trial Methodology
Society of Biological Psychiatry

EDITORIAL BOARDS: Biological Psychiatry 2008 Impact Factor – 8.4567.154

#4 of 94 Psychiatry journals and #13
of 211 Neuroscience journals
Citation rate #3 in Psychiatry and
#12 in Neurosciences
Bipolar Disorder An International Journal of Psychiatry
and Neurosciences
2007 Impact Factor – 4.443
#13 out of 94 rated psychiatric
journals
Bipolar Disorders: Reviews and Commentaries
Clinical Practice and Epidemiology in Mental Health
Current Psychosis and Therapeutics Reports
Neuropsychiatry Disease and Treatment
African Journal of Psychiatry – Advisory Board
Psychiatry– Advisory Board
Indian Journal of Psychiatry

REFEREE FOR JOURNALS:

Acta Psychiatrica Scandinavica
Adis Drug Evaluations
American Journal of Psychiatry – Impact Factor: 8.286
Annals of Neurology
Archives of General Psychiatry – Impact Factor: 12.642
Biological Psychiatry – Impact Factor: 8.456
Bipolar Disorder
CNS Drugs
European Archives of Psychiatry and Clinical Neuroscience
European Neuropsychopharmacology
European Psychiatry–Journal Assoc. European Psychiatrists
Family Practice
JAMA
Journal of Bipolar Disorder
Journal of Clinical Psychiatry – Impact Factor: 5.038
Journal of Psychopharmacology
Journal of Clin. Psychopharmacology-Impact Factor: 5.145
Journal of Psychiatric Research
International Clinical Psychopharmacology
International Journal of Neuropsychopharmacology
International Journal of Psychiatry in Medicine
The Lancet
Neurology
Neuropsychobiology
Neuropsychopharmacology – Impact Factor: 5.369
Psychiatry Research
Psychological Medicine
Psychosomatic Medicine
Psychosomatics
Schizophrenia Bulletin

Therapeutic Drug Monitoring

Mood Disorder Subspecialty Clinical Fellows, Research Fellows, Mentees:

| | |
|--------------------------------|--|
| <u>Paul Markovitz, MD, PhD</u> | 1989-1991 – Primary Mentor for Research Fellow |
| <u>Mark Woyshville, MD</u> | 1991-1992 – Primary Mentor for Research Fellow |
| <u>Neli Fu, MD</u> | 1995-1996 – Primary Mentor for Clinical Fellow |
| <u>Gretchen Gardner, MD</u> | 1994-1995 – Primary Mentor for Clinical Fellow |
| <u>Robin Bailey, MD</u> | 1992-1993 – Primary Mentor for Clinical Fellow |
| <u>Hossein Fatemi, MD, PhD</u> | 1994-1996 – Primary Mentor for Clinical Fellow |
| <u>Mary Kujawa, MD, PhD</u> | 1995-1996 – Primary Mentor for Clinical Fellow |
| <u>Omar Elhaj, MD</u> | 2003-2005 – Primary Mentor for Research Fellow - 2004 Career Development. Institute Awardee - 2004 NCDEU New Investigator Awardee |
| <u>Martha Sajatovic, MD</u> | 2003-2008 – K23 Co-Mentor 'Bipolar Disorder, Subjectivity and Treatment Adherence' |
| <u>Keming Gao, MD, PhD</u> | 2004 - 2006 Primary Mentor for Research Fellow & Faculty - 2005 NCDEU New Investigator Awardee - 2005 Career Development Institute Awardee - 2006 NARSAD Young Investigator Awardee -2008 and 2009 AstraZeneca Investigator Initiated Awards |
| Christine Baran, MD | 2005 Primary Mentor-CCLCM Summer Research Medical Student |
| <u>Michael Ostacher, MD</u> | 2006 – 2011 - K23 Off site co-Mentor |
| <u>Guohua Xia, MD, PhD</u> | 2005 - 2007 – Primary Mentor for Research Fellow - 2005 NARSAD Young Investigator Award - 2006 NCDEU New Investigator Awardee |
| <u>David Kemp, MD:</u> | 2006 – 2008 Primary Mentor for Research Fellow & Faculty - 2007 Career Development Institute Awardee for Bipolar Disorder - 2007 KL2 Clinical Research Scholar Awardee (~\$250K) <i>“Antidiabetic Drugs in the Treatment of Major Depression Co-morbid with Metabolic Syndrome”</i> - 2007 NCDEU New Investigator Awardee - 2007 ISBD Bipolar Disorders Research Fellowship Awardee (\$20K) - 2008 NARSAD Young Investigator Award (\$60K) - 2008 Grossman Family Trust Fund Junior Investigator Awardee (\$150K) - Instructor (Calabrese) for CRSP Thesis M.S. (Thesis) Class 12135 Fall 2008 & Spring 2009 |
| <u>Dorothy Sit, MD:</u> | 2008 – Off-site K23 mentor for Junior Faculty@ Univ. Pitts. 2008 – ISBD Bipolar Disorders Research Fellowship Awardee |

2009 – K23 NIMH Awardee, priority score 130
'Efficacy of Bright Light Therapy Vs. Placebo for Bipolar Depression: A Randomized'

Ronald Hickman, RN, PhD: KL2 Awardee 2008-2011 - Career Development (MAC) Mentor
'*Predicting Self-Management Capacity, Health Outcomes, and Resource Utilization in Recipients of Ventricular Assist Devices*'

Bryan Tolliver, MD, PhD: 2009 – Offsite Mentor for K23 NIAAA Awardee, priority score 153
'*Treatment of Alcohol Dependence and Co-Morbid Bipolar Disorder*'

Melissa Pinto-Foltz, RN, PhD: 2009 – KL2 Awardee – Career Development (MAC) Mentor
'*Assessment of Bias Regarding Mental Illness Across Generations Within a Family*'

RESEARCH

NIMH/FEDERAL FUNDING:

ONGOING:

1. **Bipolar Disorder Across the Life Span (P20), Developing Center for Interventions and Services Research. PI – Joseph R. Calabrese, M.D. (45%), Co-PI – Robert Findling, M.D.**

| | |
|----------------|-------------------|
| Source: | NIMH P20 MH-66054 |
| Project Dates: | 9/1/03 – 9/30/08 |
| Total Award: | \$2,967,934 |

The primary objective of this funding is to build and maintain a network of sites to conduct phenomenologic and clinical trials research that concurrently address issues of efficacy and effectiveness in underserved populations of bipolar disorder across the life cycle, including those at community mental health centers, children and adolescents, and those currently abusing alcohol and/or drugs.

2. **Lithium Treatment - Moderate dose Use Study (LiTMUS): A Randomized Controlled Effectiveness Trial Proposal from the Bipolar Trials Network. Coordinating PI: Andrew Nierenberg. Site PI: Joseph R. Calabrese, MD**

| | |
|----------------|------------------|
| Source: | NIMH Contract |
| Project Dates: | 3/1/08 – 2/28/11 |
| Total Award: | \$598,054 |

This study will assess the effectiveness of lithium added to treatment as usual (TAU) in a generalizable group of patients with bipolar disorder. Pharmacoepidemiological data suggests that lithium use has declined over the last decade and replaced with more expensive marketed medications

that may or may not result in better outcomes. The study addresses an important public health question: do tolerable doses of lithium included as part of TAU improve outcomes and decrease the need for medication changes over 6 months of follow-up?

3. Resilience and Risk Factors Associated With Combat-related Posttraumatic Psychopathology. PI – Joseph R. Calabrese, M.D. Co-PI – Marijo Tamburrino, MD. Director of Research Method Core – Sandro Galea, MD, PhD. Director of the Genetics Repository – Israel Liberzon, MD, PhD

| | |
|---|---|
| Source: | Department of Defense (DoD) Total Awards |
| | Summary: FY06 - \$4.5m |
| | FY07 - \$2.6m |
| | FY08 - \$2.8m |
| | FY09 - \$2.4m (CR as of 9/24/08) |
| | Total = \$12.3m |
| | Average per year = \$3,075,000 |
| Source 2006: | Department of Defense (DoD) |
| | FY 06 House of Representative Appropriation |
| | ARMY RDT&E |
| | Defense Research Sciences (R-1,2), pg 345 |
| | Conference Report: H.R. 109-359, 18 Dec 05 |
| | PE: 611102, Project T61, title: National |
| | Research Consortium for Stress Induced |
| | Neurochemically Based Mood Disorders |
| Project Dates: | FY 2006 |
| Total Award: | \$4,500,000 |
| Direct Award: | \$4,215,000 |
| DoD MOMRP External Indirects: | 6.822% |
| University Hospitals Indirects: | 54.5% |
| University of Toledo: | 48.3% |
| Final Award Available to Project: | \$3,496,876 |
| Source 2007: | Department of Defense |
| | FY 07 House of Representative Appropriation |
| | ARMY RDT&E |
| | Defense Research Sciences (R-1,2), page 237 |
| | Conf. Report 109-676 to HR 5631 25 Sept 06 |
| | Recurring ADD for PE: 611102, Project T61 |
| | under new title: Combat Mental Health |
| | Initiative |
| Project Dates: | FY 2007 |
| Total Award: | \$2,600,000 |
| Direct Award: | \$2,216,000 |
| DoD TATRC External Indirects: ~15.07143% | |
| Institutional Internal Indirects (F&A): 35% | |
| Final Award Available to Project: | \$1,911,665 |
| Source 2008: | Department of Defense |
| | FY 08 House of Representative Appropriation |
| | ARMY RDT&E |

Defense Research Sciences (R-1,2), page 249
 Conf. Report 110-434 to HR3222 06 Nov 2007
 Recurring ADD for PE: 611102

Under title: **Combat Mental Health Initiative**
 FY 2008

| | |
|---|-------------|
| Project Dates: | |
| Total Award: | \$2,800,000 |
| Direct Award: | \$2,378,000 |
| DoD TATRC External Indirects: ~15.07143% | |
| Institutional Internal Indirects (F&A): 35% | |
| Final Award Available to Project: | \$2,006,000 |

| | |
|--|----------------|
| Total Cumulative Award since 06', 07', 08' | \$9,900,000 |
| Total Cumulative Award after DoD indirects since 2006: | \$8,750,000 |
| Total Cumulate Award Available to Project: | \$7,414,541 |
| Average per year available to project: | \$2,471,513.60 |

The general objective of these grants is to create a research infrastructure capable of supporting a series of projects that evaluate the relationships between resilience and risk factors, both cross-sectionally and longitudinally, associated with the development of post-deployment combat-related posttraumatic psychopathology in both VA treatment seekers and non-treatment seekers. The initial project for this Initiative is an observational survey study which uses a cross-sectional study sample to form a longitudinal prospective cohort to study the relationships between pre-existing mental illness/substance use disorders, deployment to OIF or OEF, and post-deployment related mental health and overall psychosocial adjustment. The proposed study will evaluate several groups of the Ohio National Guard: 1) those deployed to OIF (Iraq, Kuwait, or Qatar), 2) those deployed OEF (Afghanistan), 3) those deployed to other areas of conflict (Bosnia, Turkey, Uzbekistan, Kosovo, on a ship, or other), 4) those deployed domestically, and 5) those not deployed. Research visits will be conducted at the time of enlistment, every 12 months for up to 10 years, and 90-180 days after each deployment. This project is designed to enroll up to 3,000 members of the Ohio National Guard between 2007 and 2010, and conduct research assessments at up to 15 time-points through 2020.

4. Bipolar Trials Network (BTN). Director: Andrew A. Nierenberg, MD; Co-Director: Lauren Marangell, MD; CWRU Site PI: Joseph R. Calabrese, MD (10%).

| | |
|----------------|---|
| Source: | Extension of Contract No. N01MH80001 (Center for Treatment of Bipolar Disorder) |
| Project Dates: | 11/05 |
| Total Award: | \$50,904 per year |

This project will be used to maintain a clinic registry database that includes contact information and relevant demographic and clinical variables. New patients who enter the Mood Disorders Program will also be tracked and the National Coordinating Center will maintain a de-identified database to track the overall characteristics of patients for all sites. IRB permission will be obtained for the pilot registry. Process and informed consent obtained. Efforts will also be made within the limits of the budget for each site to keep their clinic patients informed of new protocols through the use of newsletters, postcards, postings on websites, etc.

Committee Participation Dr. Calabrese
 Executive Committee – member

Steering Committee – Co-Chairperson
 Publication Committee – Chair
 Protocol Review Committee – Co-Chair
 Industry Liaison Committee – member
 Measurement and Assessment Committee - member

5. Acute Pharmacotherapy of Late Life Mania. Coordinating Multisite PI: Robert Young, MD, Site PI Martha Sajatovic, MD, CWRU Co-Investigator Joseph R. Calabrese, MD.

Source: NIMH R01
 Project Dates: 6/03 – 6/08
 Total Award: \$1,382,500

The first randomized, double-blind, controlled comparison of lithium and divalproex in elders with bipolar I manic, mixed, and hypomanic episodes, designed to test differences in side effects and benefits under dosing conditions relevant to geriatric practice. Hospitalized and ambulatory patients (n = 306) aged 60 years and older will be studied for 9 weeks.

FEDERAL UNDER REVIEW:

1. Pharmacogenetics of Mood Stabilizer Response in Bipolar Disorder (U01/U19). PI – Joseph R. Calabrese, M.D.

Source: RFA-GM-04-002
 Project Dates: 04/01/2010 – 03/31/2015
 Total Award: \$1,017,671
 Direct Costs: \$648,198

Mood stabilizer treatment is central to the pharmacological management of patients with bipolar disorder. However, response to such agents is highly variable between individuals often resulting in a lengthy trial and error process of medication optimization that can last years. There is a great need for a better predictor of response which would guide physicians to the optimum medication in a more efficient fashion. Genetic differences likely explain a substantial portion of this variability. The goal of this project is to identify genetic variants that are associated with response to mood stabilizer medications that might ultimately be useful as a predictive test. Our 11 site consortium has recently completed collection of over 4,500 bipolar subjects for a large genetic study. 2,000 retrospective subjects will be collected from both re-contact of these previous cases and recruitment of new retrospective cases. The prospective sample of 960 subjects will be collected through an eight site multicenter trial. Patients will be recruited, screened and stabilized first on lithium monotherapy over a 3 month period. After one month observation, they will enter the maintenance phase and followed for 2 years. The primary outcome measure will be time to relapse. Patients who fail lithium will be crossed over to valproic acid, those failing both drugs will enter the treatment as usual arm. Genomewide association will be performed on the retrospective sample and positive SNPs replicated in the prospective sample. Secondary analyses will include genomewide association of the prospective sample alone and in meta-analysis with the retrospective sample. These analyses will be guided in part by studies of lithium's mechanism of action in neuronal cells derived from induced pluripotent stem cells in turn derived from skin fibroblasts from lithium responders and non-responders.

FEDERAL COMPLETED:

1. Combination Therapy in Rapid Cycling Bipolar Disorder (R21). PI – Joseph R. Calabrese, M.D.

Source: R21 (Exploratory/Development Grant) MH-62650
 Project Dates: 2/1/2002 – 1/31/2005
 Total Award: \$573,750

The primary objective of this study is to compare the efficacy of the triple regimen lithium/divalproex/blinded lamotrigine to lithium/divalproex/placebo in the acute and continuation treatment of patients with rapid cycling bipolar disorder over a six month randomized phase.

2. Double-blind, Longitudinal Evaluation of the Efficacy and Safety of the Combination of Lithium and Divalproex Versus Lithium Monotherapy in Rapid-Cycling Bipolar Patients Who Are Abusing Alcohol, Cannabis, and/or Cocaine (RO1-S). PI – Joseph R. Calabrese, M.D.

Source: R01 MH-50165 (Supplement)
 Project Dates: 10/1/97 – 12/01
 Total Award: \$674,938

The primary objective of this study is to compare the efficacy of the combination of lithium and divalproex as compared to lithium monotherapy in the prevention of episodes in patients with rapid cycling bipolar disorder who are currently abusing alcohol, cannabis, and/or cocaine.

3. Double-Blind, Longitudinal Evaluation of the Efficacy and Safety of Divalproex and Lithium in Rapid-Cycling Bipolar Patients (RO1). PI – Joseph R. Calabrese, M.D.

Source: R01 MH-50165
 Project Dates: 4/95 to 12/01
 Total Award: \$1,232,471

The primary objective of this study was to compare the efficacy of lithium monotherapy to divalproex monotherapy in the prevention of episodes in patients with rapid cycling bipolar disorder.

4. Systematic Treatment Enhancement Program (STEP-BD) for Bipolar Disorder - A NIMH multicenter study designed to carry out a series of health effectiveness trials. Site PI – Joseph R. Calabrese, M.D.

Source: MH-98-DS-001 (subcontract from Mass. Gen'l Hospital)
 Project Dates: 8/99 - 10/1/2005
 Total Award: \$874,956

The primary objective of this study is to improve the treatment of bipolar disorder by 1) implementing model practice procedures across a network of clinicians, 2) determine the most effective somatic and psychosocial intervention strategies for the depressed phase of the illness, 3) determine which interventions most effectively prevent relapse, 4) provide a systematic means for the translation of novel treatments into clinician practice, and 5) estimate the costs and quality of life outcomes in both the acute and long-term setting.

5. Pediatric Bipolar Collaborative Mood Stabilizer Trial. Coordinating PI, Robert Kowatch, Site

**PI, Robert Findling, Senior Advisor/Unblinded Medical Monitor – Joseph R. Calabrese, M.D.
10%**

Source: R01 MH-60814
Project Dates: 9/00 to 9/04
Total Award: \$1,000,000

The primary objective of this project is to compare the efficacy of lithium, divalproex, and placebo in the acute management of mania and mixed states in children and adolescents with bipolar I disorder to test the hypothesis that divalproex and lithium are equal in efficacy and both are superior to placebo.

- 6. Center of Excellence for the Care and Study of Patients with Bipolar Disorder and Other Serious Mental Disorders Accompanied by Alcohol/Drug Abuse Across the Life Cycle. PI – Joseph R. Calabrese, M.D., Co-PI – Robert Findling, M.D.**

Source: Health Resources & Services Admin. (HRSA), U.S. Dept. HHS
1 C76 HF 00502-01
Project Dates: 8/1/02
Total Award: \$984,488

- 7. Clinical Research Center for the Study of Major Psychoses. Co-PI. - Psychopharmacology Core Joseph R. Calabrese, M.D. Herbert Meltzer, M.D. – Center Director**

Source: NIMH
Project Dates: 9/92 to 8/94

TRAINING GRANTS & SENIOR MENTORING FOR YOUNG INVESTIGATOR AWARDEES

- 1. World Psychiatric Association Center of Excellence in Psychiatric Research and Training. Primary Mentor - Joseph R. Calabrese, M.D.**

Source: World Psychiatric Association General Assembly
Projected Dates: 2009-2010
Contracted Amount: salary, travel, expenses, etc. for one research fellow from a low to middle income country

- 2. NARSAD Young Investigator Award: Glucose Lowering Drugs in the Treatment of Bipolar Depression. Young Investigator PI: David E. Kemp, MD. Senior Mentor - Joseph R. Calabrese, M.D.**

Source: NARSAD
Projected Dates: 7/08 - 7/10
Contracted Amount: \$60,000

- 3. Pioglitazone for Bipolar Depression and Comorbid Metabolic Syndrome or Insulin Resistance. PI: David E. Kemp, MD. Senior Mentor - Joseph R. Calabrese, M.D.**

Source: Cleveland Foundation/the donor-advised Grossman Family Trust
Fund for Junior Faculty
Projected Dates: 10/08 - 107/10
Contracted Amount: \$150,000

4. Influence of Metabolic Syndrome on Treatment Outcomes. PI: - David Kemp, MD. Senior Mentor - Joseph R. Calabrese, M.D.

Source: Morley Foundation
Projected Dates: 7/07-06-09
Contracted Amount: \$10,000

5. NARSAD Young Investigator Award: A Pragmatic Clinical Effectiveness Trial in Highly Multi-morbid Presentations of Anxious Patients with Bipolar I or II Depression Young Investigator PI: - Keming Gao, MD, PhD. Senior Mentor - Joseph R. Calabrese, M.D.

Source: NARSAD
Projected Dates: 7/06 - 7/08
Contracted Amount: \$60,000

6. NARSAD Young Investigator Award: Use of Transcranial Magnetic Stimulation in the Treatment of Bipolar Disorders. Young Investigator PI: - Guohua Xia, MD, PhD, Senior Mentor - Joseph R. Calabrese, M.D.

Source: NARSAD
Projected Dates: 7/06 - 7/08
Contracted Amount: \$60,000

7. Case/Cleveland Clinic Clinical Research Training Program (K12/KL2) PI: Richard Rudick, MD. Joseph R. Calabrese, MD, Research Mentor and Member Multidisciplinary Advisory Committee Member

Source: NIH K12-RR 023264
Projected Dates: 7/1/05-7/1/10

8. Antidiabetic Drugs in the Treatment of Major Depression Co-morbid with Metabolic Syndrome (K12) Awardee: David E. Kemp, MD Primary Research Mentor - Joseph R. Calabrese, M.D.

Source: NIH -RR 023264
Projected Dates: 7/1/07 - 7/1/10
Contracted Amount: \$250,000 over 3 years
\$34,711 (pilot fund, etc)

There is emerging consensus to support the existence of an overlapping pathophysiology and symptom burden between Major Depressive Disorder and the metabolic syndrome. First, this project seeks to determine if treatment with antidiabetic drugs can decrease the severity of depressive symptoms in major depressive disorder comorbid with metabolic syndrome by improving insulin

sensitivity and by reducing the release of immunoinflammatory cytokines. Second, the project will try and demonstrate the efficacy of a traditional antidepressant is not medicated by an increase in insulin sensitivity or normalization of the cytokine response.

9. Research Development Award. PI: David E. Kemp, MD, Primary Mentor: Joseph R. Calabrese, MD

Source: International Society of Bipolar Disorder
 Projected Dates: 07-07-6/08
 Contracted Amount: \$20,000

10. Research Career Development Institute for Bipolar Disorder. PI: David Kupfer, MD, Core Faculty/Mentor: Joseph R. Calabrese, MD

Source: NIMH R13 077415
 Projected Dates: 6/05-5/10
 Contracted Amount: \$60,000

A national training program with mentors who span the translational continuum of bipolar research to improve and augment research training for promising junior investigators, including those interested in basic and neuroscience, academic psychiatrists and psychologists, and health services researchers. The goal are to enhance their repertoire of research “survival skills” through an annual intensive 3-day training program coupled with annual booster sessions where senior researchers provide updates on new methods in psychiatric research and emerging trends in bipolar research

11. Research Training Fellowships in the Therapeutics of Bipolar Disorder. Director: Joseph R. Calabrese, MD

Source: GlaxoSmithKline
 Projected Dates: 9/25/03
 Total Award: \$285,000

The objective for this program is to provide a research training fellowship opportunity for board eligible adult psychiatrists to successfully compete for, and implement, high-quality, NIMH-funded research projects in the therapeutics of bipolar disorder across the life cycle.

12. Research Training Fellowships in the Therapeutics of Bipolar Disorder. Director: Joseph R. Calabrese, MD

Source: AstraZeneca
 Projected Dates: 10/17/05
 Total Award: \$334,200

The objective for this program is to provide a research training fellowship opportunity for board eligible adult psychiatrists to successfully compete for, and implement, high-quality, NIMH-funded research projects in the therapeutics of bipolar disorder across the life cycle.

13. Research Training Fellowships in the Therapeutics of Bipolar Disorder. Director: Joseph R. Calabrese, MD

Source: Lilly
 Projected Dates: 7/20/05
 Total Award: \$50,000

The objective for this program is to provide a research training fellowship opportunity for board eligible adult psychiatrists to successfully compete for, and implement, high-quality, NIMH-funded research projects in the therapeutics of bipolar disorder across the life cycle.

14. Research Training Fellowships in the Therapeutics of Bipolar Disorder. Director: Joseph R. Calabrese, MD

Source: Janssen
 Projected Dates: 9/13/04
 Total Award: \$50,000

The objective for this program is to provide a research training fellowship opportunity for board eligible adult psychiatrists to successfully compete for, and implement, high-quality, NIMH-funded research projects in the therapeutics of bipolar disorder across the life cycle.

15. Bipolar Disorder, Subjectivity and Treatment Adherence. PI – Martha Sajatovic, MD, Co-Mentor: Joseph R. Calabrese, MD

Source: NIMH K23
 Projected Dates: 9/03-9/08
 Total Award: \$810,000

A mentored patient-oriented research career development award focused on examining the relationship between the subjective experiences of patients with bipolar disorder and the impact of other factors (e.g., symptoms, gender, social support, substance) on treatment adherence. Dr. Calabrese's role as co-mentor focuses on training in design and implementation of studies in bipolar disorder.

16. NARSAD Young Investigator Award: Bipolar Disorder and Periodicity. PI – Mark J. Woyshville, MD, Senior Mentor: Joseph R. Calabrese, MD

Source: NARSAD
 Projected Dates: 9/92-8/94
 Total Award: \$60,000

FOUNDATION AWARDS:

1. Bipolar Disorder as Predictor of HIV Risk in African American Men. PI: Sana Loue, PhD. Co-PI: Joseph R. Calabrese, MD.

Source: Cleveland Foundation – donor advised fund
 Project Dates: 7/1/05 – 6/30/07
 Contracted Amount: \$118,786

2. Multicenter Study of Lithium, Divalproex, and Blinded Lamotrigine versus Lithium, Divalproex, and Placebo in the Acute and Continuation Care of Patients with Rapid Cycling Bipolar Disorder Comorbid with Alcohol, Cannabis, and/or Cocaine Abuse or Dependence– A Two Site Study. PI: Melvin D. Shelton, MD, PhD, Co-PI – Joseph R. Calabrese, M.D.

Source: Stanley Foundation # 02T-183
Project Dates: 9/02 – 9/05
Contracted Amount: \$805,230

3. Multicenter Study of Lithium, Divalproex, and Blinded Lamotrigine versus Lithium, Divalproex, and Placebo in the Acute and Continuation Care of Patients with Rapid Cycling Bipolar Disorder – A Two Site Study. PI – Joseph R. Calabrese, M.D.

Source: Stanley Foundation
Project Dates: 8/00 – 8/02
Contracted Amount: \$300,000

4. Pilot Study on the Longitudinal Evaluation of the Efficacy and Safety of Divalproex Sodium and Lithium in Rapid-Cycling Bipolar Patients. PI – Joseph R. Calabrese, M.D.

Source: Stanley Foundation
Project Dates: 7/94 - 7/97
Contracted Amount: \$150,000

5. Early Interventions in Bipolar Disorder Across the Life Cycle Clinical Research Center (Co-PI)

Source: Stanley Medical Research Institute

Projected Dates: 7/96 - 7/99
Contracted Amount: \$925,000

Project Dates: 7/99-7/03
Contracted Amount: \$1,700,00

Project Dates: 7/03-7/06
Contracted Amount: \$1,275,000

Aripiprazole vs. Placebo in the Acute and Continuation Care of At-Risk Children with Symptoms of Bipolar Disorder (Co-PI)

The primary objective of this 12 week study is to test the acute efficacy and the tolerability/safety of aripiprazole vs. placebo in 60 outpatient children ages 5-17 with subsyndromal symptoms of bipolar disorder who are genetically at risk for developing bipolar disorder as defined by one parent with bipolar disorder and one first or second degree relative with a mood disorder and non-responders to a course of psychotherapy.

Aripiprazole vs. Placebo in Maintenance Therapy for Children Presenting with Symptoms of Mania

The primary objective of this 72 week study is to test the efficacy and the tolerability/safety of aripiprazole vs. placebo in 150 outpatient pre-schoolers ages 4-9 present with symptoms of mania.

6. Affective Instability: Quantification, Conceptualization, and Clinical Significance. PI: - Mark Woynshville, Mentor - Joseph R. Calabrese, M.D.

Source: NARSAD
Projected Dates: 7/94 - 7/96
Contracted Amount: \$60,000/year

7. Prevalence of post operative delirium following urgent coronary artery bypass grafting. PI: - Joseph R. Calabrese, M.D.

Source: Cleveland Clinic Foundation
Projected Dates: 1982-1984
Contracted Amount: \$25,000

PHARMACEUTICAL RESEARCH GRANTS:

1. Efficacy and Safety of LuAA39959in Bipolar I or II Depression. Joseph R. Calabrese, MD (Coordinating PI), David E Kemp, MD (Site-PI)

Source: Lundbeck
Project Dates: 1/09-12/09
Contracted Amount: 83,162

2. An 8-Week Double-Blind, Placebo-Controlled Parallel Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder.

Source: Cephalon
Project Dates: 8/07-6/08
Amount Received: 0

3. A Double-Blind, Randomized, Multicenter, Parallel Study to Evaluate the Efficacy and Safety of Quetiapine and Placebo in Currently Depressed Subjects with Bipolar I or II Disorder (BOLDER I). Primary Consultant and Site-PI: Joseph R. Calabrese, M.D.

Source: AstraZeneca
Project Dates: 12/02-12/-03
Contracted Amount: \$135,750

4. A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients with Bipolar Disorder. Site-PI – Joseph R. Calabrese, M.D.

Source: BMS
Project Dates: 5/05/11/05
Contracted Amount: \$279,220

5. Treatment of patients with major depressive disorder with melancholic features. Site-PI – Joseph R. Calabrese, M.D.

Source: Merck
Project Dates: 10/01 – 2/03
Contracted Amount: \$122,287

6. Olanzapine in Treatment Refractory Mania. PI – Joseph R. Calabrese, M.D., Co-PI: David Muzina

Source: Lilly
Project Dates: 5/1/01 – 4/02
Contracted Amount: \$241,000

7. Evaluation of the Safety and Efficacy of Escitalopram in the Prevention of Depression Recurrence. Site-PI – Joseph R. Calabrese, M.D.

Source: Forest Labs
Project Dates: 10/00 – 10/01
Contracted Amount: \$125,000

8. A Double-Blind Controlled Study Comparing Two Doses of Lamotrigine to Placebo in the Treatment of Bipolar I Depression (40910). PI – Joseph R. Calabrese, M.D.

Source: Glaxo Wellcome
Project Dates: 11/00 – 11/01
Contracted Amount: \$150,000

9. A Multicenter Study of the Efficacy and Safety of Levetiracetam in Acute Mania in Adults with Bipolar Disorder. Site-PI – Joseph R. Calabrese, M.D.

Source: UCB Pharma
Project Dates: 11/00 – 11/0
Contracted Amount: \$100,000

10. Phase II Multicenter Randomized Comparison of Three Doses of TAK-637 (a substance P antagonist) Versus Placebo in the Treatment of Subjects with Major Depressive Disorder. Site-PI – Joseph R. Calabrese, M.D.

Source: Tap Holdings Inc.
Project Dates: 3/00 – 2/01
Contracted Amount: \$183,880

11. Flexible Dose Comparison of the Safety and Efficacy of Lu 26-054, Citalopram, and Placebo in the Treatment of Major Depression. Site-PI – Joseph R. Calabrese, M.D.

Source: Forest Laboratories, Inc.
Project Dates: 9/99 – 4/00
Contracted Amount: \$87,800

12. Placebo-Controlled Evaluation of the Safety and Efficacy of Lu 26-054 in the Prevention of Depression Relapse. Site-PI – Joseph R. Calabrese, M.D.

Source: Forest Laboratories, Inc.
Project Dates: 9/99 – 9/01
Contracted Amount: \$135,558

13. A Multicentre, Double-Blind, Placebo-Controlled, Flexible-Dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long Term Treatment of Patients Who Have Bipolar Disorder With Rapid Cycling (611). Site-PI – Joseph R. Calabrese, M.D.

Source: Glaxo Wellcome, Inc.
Projected Dates: 1/99 - 5/99
Contracted Amount: \$80,000

14. A Multicenter, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Lamotrigine Compared to Placebo in the Treatment of an Acute Hospitalized Manic or Mixed Episodes in Patients Who Have Bipolar Disorder (609). Site-PI – Joseph R. Calabrese, M.D.

Source: Glaxo Wellcome, Inc.
Projected Dates: 1/99 - 1/2000
Contracted Amount: \$125,000

15. An Open-Label Evaluation of the Efficacy, Safety and Dosing of Citalopram in Outpatients With Depression. Site-PI – Joseph R. Calabrese, M.D.

Source: Forest Laboratories, Inc.
Projected Dates: 7/98 - 3/99
Contracted Amount: \$30,000

16. Citalopram Treatment of Depressed Patients Discontinued For Paroxetine Adverse Events. Site-PI – Joseph R. Calabrese, M.D.

Source: Forest Laboratories, Inc.
Projected Dates: 7/98 - 3/99
Contracted Amount: \$30,000

17. Citalopram Treatment of Depressed Patients Discontinued From Fluoxetine For Adverse Events. Site-PI – Joseph R. Calabrese, M.D.

Source: Forest Laboratories, Inc.
Projected Dates: 7/98 - 3/99
Contracted Amount: \$30,000

18. A Multicentre, Double-Blind, Placebo-Controlled, Fixed-Dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long Term Treatment of Patients Who Have Bipolar I and II Disorder With Rapid Cycling (614). Primary Consultant and Site PI – Joseph R. Calabrese, M.D.

Source: Glaxo Wellcome, Inc.
Projected Dates: 4/96 - 7/99
Contracted Amount: \$98,028

19. An Open, Multicentre, Flexible-Dose Continuation Study of Lamotrigine in Patients with Bipolar

Disorder (604). Site-PI – Joseph R. Calabrese, M.D.

Source: Glaxo Wellcome, Inc.
Projected Dates: 6/96 - 7/98
Contracted Amount: \$48,600

20. A Multicentre, Double-Blind, Placebo-Controlled, Randomized, Fixed-Dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long Term Prevention of Relapse and Recurrence of Depression and/or Mania in Patients with Bipolar I Disorder Presenting Depressed (605). Primary Consultant and Site-PI – Joseph R. Calabrese, M.D.

Source: Glaxo Wellcome, Inc.
Projected Dates: 5/97 - 10/99
Contracted Amount: \$192,215

21. A Multicentre, Double-Blind, Double Dummy, Placebo and Lithium-Controlled, Randomized, Fixed-Dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long-Term Prevention of Relapse and Recurrence of Mania and/or Depression in Patients with Bipolar I Disorder Presenting Manic (606). Site-PI – Joseph R. Calabrese, M.D.

Source: Glaxo Wellcome, Inc.
Projected Dates: 5/97 - 10/99
Contracted Amount: \$136,771

22. A Double-Blind Controlled Study Comparing Lamotrigine to Placebo in the Treatment of Bipolar I Depression (602). PI – Joseph R. Calabrese, M.D.

Source: Glaxo Wellcome, Inc.
Projected Dates: 7/97 - 7/99
Contracted Amount: \$132,070

23. An Open, Multicentre, Prospective Evaluation of the Spectrum of Efficacy of Lamotrigine in Bipolar I and II Disorder (601). Primary Consultant and Site PI – Joseph R. Calabrese, M.D.

Source: Burroughs Wellcome
Project Dates: 12/94 - 12/96
Contracted Amount: \$61,812

24. Olanzapine Added to Mood Stabilizers in the Treatment of Bipolar Disorder. PI –Joseph R. Calabrese, M.D.

Source: Lilly Research
Project Dates: 9/1/97 - 9/1/99
Contracted Amount: \$226,250

25. Gabapentin Adjunctive Treatment in Patients with Bipolar Disorder. Site-PI – Joseph R. Calabrese, M.D.

Source: Parke-Davis / Warner Lambert
Projected Dates: 5/96 - 7/97

Contracted Amount: \$62,060

26. Topiramate Pilot, Open-Label Safety and Tolerability Trial in Adults with Acute Mania Protocol. Site PI – Joseph R. Calabrese, M.D.

Source: R.W. Johnson Pharmaceutical Research Institute
Projected Dates: 12/96 – 5 /97
Contracted Amount: \$24,706

27. Double-Blind, Placebo-Controlled, Parallel Group, Comparative Study of Venlafaxine and Fluoxetine in Depressed Outpatients to Measure Onset of Clinical Activity. Site-PI – Joseph R. Calabrese, M.D.

Source: Wyeth Ayerst
Projected Dates: 9/95 - 9/96
Contracted Amount: \$249,102

28. Double-Blind, Longitudinal Evaluation of the Efficacy and Safety of Divalproex Versus Lithium and Placebo in Bipolar Disorder. Primary Consultant and Site-PI – Joseph R. Calabrese, M.D.

Source: Abbott Laboratories
Project Dates: 5/93 to 4/96
Contracted Amount: \$307,544

29. A Double-Blind, Placebo-Controlled, Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression. Site-PI – Joseph R. Calabrese, M.D.

Source: SmithKline Beecham
Project Dates: 1/94 to 1/95
Contracted Amount: \$119,280

30. Amesergide/Fluoxetine/Placebo in Major Depressive Disorder. Site-PI – Joseph R. Calabrese, M.D.

Source: Lilly Research Laboratories
Project Dates: 4/92 to 12/92
Contracted Amount: \$352,150

31. A Phase II, Multicenter, Randomized, Double-Blind, Dose Finding Study of Three Different Doses of Roxindole vs. Placebo in Outpatient Suffering from Depression. Site-PI – Joseph R. Calabrese, M.D.

Source: E. Merck
Project Dates: 5/93 to 6/94
Contracted Amount: \$137,525

32. A Pilot Study Evaluating the Safety and Efficacy of Clozapine in the Acute Management of Refractory Bipolar and Schizoaffective Mania. PI - Joseph R. Calabrese, M.D.

Source: Sandoz Pharmaceuticals
Project Dates: 12/92 to 12/93
Contracted Amount: \$75,250

33. Comparison of the Efficacy and Safety of Divalproex and Lithium in the Treatment of the Manic Phase of Bipolar Disorders: A Placebo-Controlled Study. Site-PI – Joseph R. Calabrese, M.D.

Source: Abbott Laboratories
Project Dates: 8/90 to 5/92
Contracted Amount: \$97,440

34. Safety of Divalproex in Manic Patients: A Retrospective Case Study. PI – Joseph R. Calabrese, M.D.

Source: Abbott Laboratories
Project Dates: 1/92 to 6/92
Contracted Amount: \$45,625

35. Divalproex Therapy in Patients Previously Randomized to Divalproex in Abbott Study M87-016 or M88-267: A Retrospective Cohort Study. Site-PI – Joseph R. Calabrese, M.D.

Source: Abbott Laboratories
Project Dates: 3/92 to 7/92
Contracted Amount: \$2,441

34. DSM-IV Rapid-Cycling Study. Site-PI - Joseph R. Calabrese, M.D.

Source: MacArthur Foundation
Project Dates: 5/91 to 8/91
Contracted Amount: \$1,000

35. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Comparison of Paroxetine and Fluoxetine in the Treatment of Major Depressive Disorder. Site-PI – Joseph R. Calabrese, M.D.

Source: SmithKline Beecham Pharmaceuticals
Project Dates: 4/91 to 2/92
Contracted Amount: \$116,120

36. Biology of Mania: Mechanism of Action of Mood Stabilizers. PI – Joseph R. Calabrese, M.D.

Source: Abbott Laboratories
Project Dates: 8/90 to 5/92
Contracted Amount: \$5,000

37. Double-Blind, Placebo-Controlled Trial of Fluoxetine in the Treatment of Borderline Personality Disorder. Co-PI - Joseph R. Calabrese, M.D.

Source: Lilly Research Laboratories
Project Dates: 9/90 - 12/91
Contracted Amount: \$47,833

Selected Invited Presentations (2005 forward)

1. “Research Training Before, During, and After Psychiatry Residency Training” Presented to St. Louis University Department of Psychiatry Grand Rounds, St. Louis, Missouri, February 8,

- 2005.
2. "Dealing With Depression" Presented for symposium Managing Psychiatric Illness: Time to Raise Expectations at Budapest Congress Centre, Budapest, Hungary, February 16, 2005.
 3. "Optimal Treatment of Patients With Bipolar Disorder" Presented for symposium Managing Psychiatric Illness: Time to Raise Expectations at Budapest Congress Centre, Budapest, Hungary, February 16, 2005.
 4. "Misdiagnosis of Bipolar Disorder and New Treatments" Presented to SOPSI 2005 (Simposio Collaborazione SOPSI-Industria) Satellite Symposium entitled Clinical Strategies in Managing Schizophrenia and Bipolar Disorder, Rome, Italy, February 25, 2005.
 5. "Psychosocial Impairment Associated With Bipolar Depression and Its Treatment" Presented to SOPSI 2005 (Simposio Collaborazione SOPSI-Industria) Magistrale Lettura, Rome, Italy, February 25, 2005.
 6. "Impact of Bipolar Depression" Presented to National Advisory Board, Savannah, Georgia, March 31, 2005.
 7. "New and Old Treatments for Bipolar Depression" Presented as Mini Symposium, Amsterdam, Netherlands, April 5, 2005.
 8. "Long Term Drug Therapy" Presented to 5th International Review of Bipolar Disorder (5th IRBD), Symposium entitled Long Term Care, Lyon, France, April 22, 2005.
 9. "The Translational Research Continuum" Presented to 2005 Career Development Institute for Bipolar Disorder, Ft. Lauderdale, Florida, May 1, 2005.
 10. "Career Advancement – Creating an Effective Curriculum Vitae, Writing & Publication Strategies" Presented to 2005 Career Development Institute for Bipolar Disorder, Ft. Lauderdale, Florida, May 2, 2005.
 11. "IRB, Bioethical Issues & Conflict of Interest" Presented to 2005 Career Development Institute for Bipolar Disorder, Ft. Lauderdale, Florida, May 2, 2005.
 12. "Overview of Bipolar Depression" Presented to Investigator Meeting, Miami, Florida, May 6, 2005.
 13. "Dual Diagnosis Bipolar Disorder and The Department of Corrections" Presented to University of Texas Health Science Center Department of Psychiatry Grand Rounds, San Antonio, Texas, May 10, 2005.
 14. "Research Training During and After Psychiatry Residency" Presented to University of Texas Health Science Center Resident Psychiatry Lecture, San Antonio, Texas, May 10, 2005.
 15. "What Psychiatry Residents Can Expect From an NIMH-Funded Research Fellowship" Presented to Stanford University Department of Psychiatry Grand Rounds, Stanford, California, May 12, 2005.
 16. "Issues in Treating Bipolar Depression" Presented to American Psychiatric Association Satellite Symposium entitled Bipolar Disorder: Treating Through the Entire Spectrum, Atlanta, Georgia, May 22, 2005.
 17. "Key Components of Research Training Core Curriculum" Presented to American Psychiatric Association Workshop entitled Research Training and Career Development: NIMH Opportunities, Atlanta, Georgia, May 23, 2005.
 18. Treatment of Mental Illness in U.S. Jails & Prisons Workshop. Presented to American Psychiatric Association, Atlanta, Georgia, May 25, 2005.
 19. "Treatment of Rapid Cycling Bipolar Disorder" Presented to American Psychiatric Association, Review of Psychiatry entitled Advances in the Treatment of Bipolar Disorder, Atlanta, Georgia, May 25, 2005.
 20. "Effect of Psychotropic Drugs on Suicidality" Panel Chair. Presented to 45th NCDEU Meeting,

Ft. Lauderdale, Florida, June 7, 2005.

21. "Managing Substance Abuse in Patients With Bipolar Disorder" Presented to 6th International Conference on Bipolar Disorder, Pittsburgh, Pennsylvania, June 16, 2005.
22. "What Psychiatry Residents Can Expect From NIMH-Sponsored Research Training" Co-Chair and Speaker. Presented to 6th International conference on Bipolar Disorder, Pittsburgh, Pennsylvania, June 18, 2005.
23. "Pregnancy Outcomes Over 11 Years of Monitoring in the International Lamotrigine Pregnancy Registry". Presented at the 2005 World Congress of Biological Psychiatry. Vienna, Austria, June 29, 2005.
24. "Research Training During and After Psychiatry Residency". Department of Psychiatry Grand Rounds. Louisiana State University, Shreveport, Louisiana. September 23, 2005.
25. "Legal Complications of Bipolar Disorder". Evidence-Based Treatment for Forensic Psychiatry. Institute of Psychiatry at the Maudsley, King's College London, University of London, UK. October 13, 2005.
26. "Quetiapine (300mg, 600mg) vs. Placebo in Acute Bipolar I or II Depression: The Bolder II Study." European College of Neuropsychopharmacology. Amsterdam, The Netherlands. October 24, 2005.
27. Phenomenology and Treatment of Dual Diagnosis Bipolar Disorder. Canadian Psychiatric Association, November 4, 2005.
28. Deployment Mental Health. Dept. of Psychiatry Grand Rounds, University Hospitals of Cleveland. Cleveland, Ohio, November 11, 2005.
29. Overview of Depression and Bipolar Disorder. Dept. of Neurology Grand Rounds, University Hospitals of Cleveland, Cleveland, Ohio, January 6, 2006.
30. Medication Treatment for Bipolar Disorder. Fund development effort for NARSAD, Sarasota, Florida, January 7, 2006.
31. New Research Regarding Bipolar Disorder. Italian Society of Psychopathology, Rome, Italy, February 24, 2006.
32. Medication Treatment for Bipolar Disorder. Fund development effort for NARSAD, Palm Beach, Florida, January 7, 2006.
33. Treatment of Bipolar Depression with the Atypical Antipsychotic Agents vs. the Anticonvulsants, Annual CME meeting of the Psychiatric Annals, NY, NY, March 24, 2006.
34. New Research Finding in Bipolar Depression. April 7, 2006. Argentine Society of Biological Psychiatry. Buenos Aires, Argentina. April 6-7, 2006.
35. 2nd Annual Career Development Institute for Junior Faculty and Research Fellows in Bipolar Disorder. April 30, 2006, Boca Raton, Florida.
36. Treatment of Bipolar Disorder in US Jails and Prisons. Annual meeting of the American Psychiatric Association. Toronto, Canada. May 20, 2006.
37. Management of Side Effects Associated With New Treatments for Bipolar Depression. Annual meeting of the American Psychiatric Association. Toronto, Canada. May 22, 2006.
38. US and International Perspectives on the Canadian Guidelines for Bipolar Disorder. Annual meeting of the American Psychiatric Association. Toronto, Canada. May 22, 2006.
39. Methodological Considerations in the Study of Long-term Bipolar Depression. Annual meeting of the International Society of Clinical Trial Methodology. Chicago, July 8, 2006.
40. Management of Side Effects Associated with New Treatments for Depressive Symptoms in Bipolar Disorder. Annual meeting of the European College of Neuropsychopharmacology. Paris, France, September 18, 2006.
41. New Findings on the Short- and Long-term Management of Bipolar Depression. Lectures @

- Tainan, Taiwan sponsored by the National Cheng Kung University; Taichung, Taiwan sponsored by the Taichung Veterans General Hospital; Kaohsiung, Taiwan sponsored by the Chang Gung University; Taipei, Taiwan co-sponsored by the Taipei Medical University and the National Yang-Ming University; and Hong Kong sponsored by the Hong Kong College of Psychiatrists. October 14-25, 2006.
42. Deployment Mental Health During the Global War on Terror. Cleveland Psychiatric Society. Cleveland, Ohio. February 7, 2007.
 43. Risk and Resilience Research Supported by the OHIOCARES Program. Joining Forces meeting. May 30, 2007. Columbus, Ohio.
 44. Update on the Treatment of Bipolar I Depression. International Conference on Bipolar Disorders. June 7, 2007. Pittsburgh, PA.
 45. Plenary Lecture: Side Effect Management in the Treatment of Bipolar Depression. Co-sponsored by the Japanese Society of Biological Psychiatry and the Japanese Society of Neuropsychopharmacology. July 13, 2007. Sapporo, Japan.
 46. New Research on the Acute and Long-term Treatment of Bipolar Depression. Co-sponsored by the Japanese Society of Biological Psychiatry and the Japanese Society of Neuropsychopharmacology. July 12, 2007. Sapporo, Japan.
 47. Efficacy and Tolerability of Quetiapine Compared with Placebo When Used in Combination with Lithium or Divalproex in the Maintenance Treatment of Bipolar I disorder in Adult Patients – Multicentre, Randomized, Parallel-group, Double-blind, Pooled, Placebo-controlled Phase III Studies 126 and 127. Presented for the first time on October 13, 2007 at the Annual meeting of the European College of Neuropsychopharmacology. Vienna, Austria.
 48. New Research Regarding the Short- and Long-term Treatment of Bipolar Depression. Presented at the 2008 annual meeting of the Italian Society of Psychopathology. February 21, 2008, Rome, Italy.
 49. New Research Regarding the Short- and Long-term Management of Bipolar Disorder. Presented at the 2008 annual meeting of the International Society of Bipolar Disorders. January 27, 2008. New Delhi, India.
 50. New Research on the Short-term Treatment of Bipolar Depression. Presented at the 2008 annual meeting of the European College of Neuropsychopharmacology. August 30, 2008. Barcelona, Spain.
 51. Research Update in Bipolar Disorder. Grand Rounds, Brecksville VAMC, September 19, 2008.
 52. New Research on the Long-term Management of Bipolar Disorder. Presented at the 2008 annual meeting of the Korean Society of Neuropsychopharmacology. October 9, 2008. Seoul, South Korea.
 53. Plenary Lecture at the 2008 Annual meeting of the Asian Pacific Psychiatry. October 8, 2008. Singapore. International Symposium, Madrid, Spain. Maintenance Research into Bipolar Disorder Treatment. February 10, 2009.
 54. International Society of Clinical Trial CNS Methodology. Arlington, VA. Trial Methodology for Maintenance Studies in Bipolar Depression.
 55. Zucker Hillside Hospital. Dept. of Psychiatry Grand Rounds. Overview of the New Treatments in Bipolar Disorder. Glen Oaks, NY.
 56. Dutch Psychiatric Association. Which Treatment Decisions in Bipolar Disorder Are Really Evidenced Based. Groningen, The Netherlands. March 31. 2009.
 57. Dutch Psychiatric Association. New Options in the Acute Treatment of bipolar Depression. Groningen, The Netherlands. April 1, 2009.
 58. World Psychiatric Association. Florence, Italy. New Research Regarding the Phenomenology

- and Treatment of Bipolar Mixed Depression. April 2, 2009
59. World Psychiatric Association. Florence, Italy. New Options in the Short-term Treatment of Bipolar Disorder. April 3, 2009.

PUBLICATIONS

Peer-Reviewed Papers:

1. **Calabrese JR**, Gullledge AD: Thyroid dysfunction and lithium. *Cleve Clinic Quarterly* 1983 Spring;50(1):32-3.
2. **Calabrese JR**, Gullledge AD: Depression and hypothyroidism. *JAMA* 1983 Nov 11;250(18):2470-1.
3. **Calabrese JR**, Gullledge AD: Prostaglandin E2 and depression. *Biol Psychiatry* 1984 Aug;19(8):1269-70.
4. Chrousos GP, **Calabrese JR**, Avgerinos PC, Kling MA, Rubinow DR, Oldfield EH, Schuermeyer TH, Kellner CH, Cutler GB, Loriaux DL, Gold PW: Corticotropin-releasing factor: Basic studies and clinical applications. *Prog Neuropsychopharmacol Biol* 1985;9(4):349-59.
5. **Calabrese JR**, Gullledge AD: Psychotropics during pregnancy and lactation: A Review. *Psychosomatics* 1985 May;26(5):413-6, 424-6.
6. **Calabrese JR**, Gullledge AD, Hahn K, Skwerer RG, Gupta MK, Schumacher OP, Gold PW: Autoimmune thyroiditis in lithium-treated manic depression. *Am J Psychiatry* 1985 Nov;142(11):1318-21.
7. **Calabrese JR**, Gullledge AD: Neonatal narcotic abstinence syndrome: A Review. *Can J Psychiatry* 1985 Dec;30(8):623-6.
8. **Calabrese JR**, Skwerer RG, Gullledge AD, Barna B, Valenzuela R, Butkus A: Depression, immunocompetence, and prostaglandins of the E series. *Psychiatry Research* 1986 Jan;17(1):41-7. {cited by 56}
9. Gold PW, **Calabrese JR**, Kling MA, Avgerinos PC, Khan I, Gallucci WT, Chrousos G: Abnormal ACTH and cortisol responses to ovine corticotropin-releasing factor. *Prog Neuropsychopharmacol Biol Psychiatry* 1986;10(1):57-65. {cited by 14}
10. Gold PW, Loriaux DL, Roy A, Kling MA, **Calabrese JR**, Kellner CH, Post RM, Pickar D, Avgerinos PC, Paul SM, Schulte HM, Oldfield EH, Cutler GB, Chrousos G: Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease: Pathophysiologic and diagnostic implications. *N Engl J Med* 1986 May 22;314(21):1329-35.
11. **Calabrese JR**, Gullledge AD: Carbamazepine, clonazepam use during pregnancy. *Psychosomatics* 1986 Jun;27(6):464.
12. Gold PW, Kling MA, **Calabrese JR**, Kalogeros K, Post RM, Avgerinos PC, Loriaux DL, Chrousos G: Corticotropin-releasing hormone: Relevance to normal physiology and to the pathophysiology and differential diagnosis of hypercortisolism and adrenal insufficiency. *Adv Biochem Psychopharmacol* 1987;43:183-200.

13. **Calabrese JR**, Skwerer RG, Gulledge AD, Gill CG, Mullen JD, Rodgers DA, Taylor PC, Golding LA, Lytle BW, Cosgrove DM, Bazarel MG, Loop FD: Incidence of postoperative delirium following myocardial revascularization: A prospective study. *Cleve Clinic J Med* 1987 Jan-Feb;54(1):29-32.
14. Gold PW, Kling MA, **Calabrese JR**, Post RP, Roy A, Nieman LK, Cutler GB, Loriaux DL, Chrousos G: Corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. *N Engl J Med* 1987;316:217-219.
15. **Calabrese JR**, Kling MA, Gold PW: Alterations in immunocompetence during stress, bereavement, and depression: Focus on the interplay between the immunologic apparatus and neuroendocrine regulation. *Am J Psychiatry* 1987 Sep;144(9):1123-34.
16. Gulledge AD, **Calabrese JR**: Diagnosis of anxiety and depression. *Med Clinics N America* 1988 Jul;72(4):753-63.
17. Kling MA, Whitfield HJ, Brandt HA, Demitrack MA, Kalogeras K, Geraciotti TD, Perini GI, **Calabrese JR**, Chrousos GP, Gold PW: Effects of glucocorticoid antagonism with RU 486 on pituitary adrenal function in patients with major depression: time-dependent enhancement of plasma ACTH secretion. *Psychopharmacol Bull* 1989;25(3):466-72.
18. Rapport DJ, **Calabrese JR**: Carbamazepine effect on birth control pills. *Psychosomatics* 1989 Fall;30(4):462-4.
19. **Calabrese JR**: Immunocompetence during stress and depression. *Am J Psychiatry* 1988;145:536-537.
20. Onady AA, **Calabrese JR**: Carbamazepine and hetero-induction complicating clinical care. *J Clin Psychopharm* 1989 Oct;9(5):387-8.
21. **Calabrese JR**: Management of Depression: Both drugs and psychotherapy are needed. *Cleve Clinic J Med* 1989;56:13-14.
22. Delucchi AG, **Calabrese JR**: Anticonvulsants for treatment of manic depression. *Cleve Clinic J Med* 1989 Nov-Dec;56(8):756-61.
23. Markovitz P, **Calabrese JR**: Anticonvulsants in manic depression during pregnancy. *Psychosomatics* 1990 Winter;31(1):118.
24. **Calabrese JR**, Delucchi GA: Spectrum of efficacy of divalproex in 55 rapid-cycling manic depressives. *Am J Psychiatry* 1990 Apr;147(4):431-4.
25. Markovitz P, Stagno S, **Calabrese JR**: Buspirone potentiation of fluoxetine in the treatment of obsessive compulsive disorder. *Am J Psychiatry* 1990 Jun;147(6):798-800.
26. Pycha C, **Calabrese JR**, Gulledge AD, Maloney JD: Psychosocial adaptation to implantable cardioverter defibrillators. *Cleve Clinic J Med* 1990 Ju-Aug;57(5):441-4.
27. Gadde K, **Calabrese JR**: Diltiazem effect on carbamazepine levels in manic depression. *J Clin Psychopharmacology* 1990 Oct;10(5):378-9.

28. Delucchi GA, **Calabrese JR**: Phenomenology of the intractable bipolar patient: Focus on the role of rapid cycling. *Acta Psiquiatrica y Psicologica de America Latina*, 1990.
29. Kling MA, Roy A, Doran A, **Calabrese JR**, Rubinow D, Whitfield H, May C, Post R, Chrousos G, Gold PW: Cerebrospinal fluid immunoreactive corticotropin releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: Potential clinical implications. *J Clin Endocrinol Metab* 1991 Feb;72(2):260-71.
30. **Calabrese JR**, Markovitz PJ: Treatment of depression: New pharmacologic approaches. *Prim Care*. 1991 Jun;188(2):421-33.
31. Markovitz PJ, **Calabrese JR**, Schulz SC, Meltzer HY: Fluoxetine in borderline and schizotypal personality disorder. *Am J Psychiatry* 1991 Aug;148(8):1064-7.
32. **Calabrese JR**, Meltzer HY, Markovitz PJ: Clozapine prophylaxis in rapid-cycling bipolar disorder. *J Clin Psychopharmacology* 1991 Dec;11(6):397-8.
33. Delucchi GA, **Calabrese JR**: Fenomenologia del paciente bipolar intractable: Enfoque en el rol del ciclaje rapido. *Alcmeon* 1991;4(1):535-546. ISSN 0327-3954, ISSN 1514-09862
34. **Calabrese JR**, Markovitz PJ, Kimmel SE, Wagner SC: Spectrum of efficacy of valproate in 78 rapid cycling manic depressives. *J Clin Psychopharmacol*. 1992 Feb;12:53-56.
35. Maes M, Scharpe S, Meltzer HY, Suy E, Cosyns P, **Calabrese JR**: Lower angiotensin I converting enzyme activity in melancholic subjects: A pilot study. *Biol Psychiatry* 1992 Oct 1;32(7):621-624.
36. Kling MA, Rubinow DR, Doran AR, Roy A, Davis CL, **Calabrese JR**, Nieman LK, Post RM, Chrousos G, Gold PW: Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: Relationship to indices of corticotropin-releasing hormone and cortisol secretion. *Neuroendocrinology* 1993 Jan;57(1):79-88.
37. Maes M, Meltzer H, Jacobs J, Suy E, **Calabrese JR**, Minner B, Raus J: Autoimmunity in depression: Increase antiphospholipid autoantibodies. *Acta Psychiatr Scand* 1993 Mar;87(3):160-6.
38. Maes M, Meltzer H, Suy E, **Calabrese JR**, Minner B, Cosyns P: Sleep disorders and anxiety symptom profiles of sympathoadrenal system hyperactivity in major depression. *J Affective Disorders* 1993 Mar;27(3):197-207.
39. Maes M, Meltzer H, Cosyns P, **Calabrese JR**: Pituitary and adrenal hormone responses to Synacthen in melancholic subjects vs. subjects with minor depression. *Biol Psychiatry* 1993 Apr 15-May;33(8-9):624-9.
40. **Calabrese JR**, Rapport DJ, Kimmel SE, Woyshville MJ: Rapid cycling bipolar disorder and its treatment with valproate. *Can J Psychiatry* 1993 Apr;38(3 Suppl 2):S57-61.
41. **Calabrese JR**, Woyshville MJ, Kimmel SE, Rapport DJ: Mixed states and bipolar rapid cycling and their treatment with valproate. *Psychiatric Annals* 1993;23:70-78.
42. Maes M, Meltzer HY, Scharpe S, Cooreman W, Uyttenbroeck W, Suy E, Vandervorst C, **Calabrese JR**, Raus J, Cosyns P: Psychomotor retardation, anorexia, weight loss, sleep disturbances, and loss of

- energy: Psychopathological correlates of hyperhaptoglobinemia during major depression. *Psychiatry Research* 1993 Jun;47(3):229-241.
43. Maes M, Dieryck R, Meltzer H, Engels M, **Calabrese JR**, Cosyns P: Regional cerebral blood flow in unipolar depression measured with TC-99M-HMPAO SPECT SCAN: Negative findings. *Psychiatry Research* 1993;50:77-88.
 44. **Calabrese JR**, Woyshville MJ, Kimmel SE, Rapport DJ: Predictors of valproate response in bipolar rapid cycling. *J Clin Psychopharmacology* 1993 Aug;13(4):280-3.
 45. Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, **Calabrese JR**, Cosyns P: Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic pituitary adrenal axis in severe depression. *Psychiatry Research* 1993 Oct;49(1):11-27.
 46. Rapport DJ, **Calabrese JR**: Tolerance to fluoxetine. *J Clin Psychopharmacology* 1993 Oct;13(5):361.
 47. Maes M, Meltzer HY, Scharpe S, Bosmans E, Suy E, Meester I, **Calabrese JR**, Cosyns P: Relationships between lower plasma L-tryptophan levels and immune inflammatory variables in depression. *Psychiatry Research* 1993 Nov;49(2):151-165.
 48. Khaitan L, **Calabrese JR**, Stockmeier CA: Effects of chronic treatment with valproate on serotonin-1A receptor binding and function. *Psychopharmacology (Berl)*. 1994 Jan;113(3-4):539-42.
 49. Maes M, Meltzer H, Blockx P, Cosyns P, **Calabrese J**: Ultrasensitive assay for measuring the intact (1-39) ACTH molecule: an asset in depression research. *Neuropsychobiology*. 1994;29(4):168-73.
 50. Maes M, **Calabrese JR**, Lee M, Meltzer H: Effect of age on hypercortisolemia in normal volunteers and depression. *Psychoneuroendocrinology* 1994;19(1):79-84.
 51. Woyshville MJ, **Calabrese JR**: Quantification of occipital EEG in Alzheimer's disease utilizing a new metric: The fractal dimension. *Biol Psychiatry* 1994 Mar;15;35(6):381-7.
 52. Bowden CL, Brugger AM, Swann AC, **Calabrese JR**, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD: Efficacy of divalproex and placebo in the treatment of mania. The Depakote Mania Study Group. *JAMA* 1994 Mar;271(12):918-24.
 53. Bauer MS, **Calabrese JR**, Dunner DL, Post R, Whybrow PC, Gyulai L, Tay LK, Younkin S, Bynum D, Lavori P, Price A: Multi-Site Data Reanalysis: Validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. *Am J Psychiatry* 1994 Apr;151(4):506-515.
 54. Maes M, **Calabrese JR**, Meltzer H: The relevance of the inpatient versus outpatient status of studies on HPA-axis in depression: Spontaneous hypercortisolism is a feature of major depressed inpatients and not for major depression per se. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 1994 May;18(3):503-517.
 55. Maes M, Meltzer H, Stevens W, **Calabrese JR**, Cosyns P: Natural killer cell activity in major depression: Relationships to natural killer cell, indices of in vivo systemic immune activation, and depressive phenomenology. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 1994 July;18(4):717-730.

56. Kimmel SE, **Calabrese JR**, Woysville MJ, Meltzer HY: Clozapine in treatment refractory mood disorders. *J Clin Psychiatry* 1994 Sept;55:91-3.
57. Maes M, Meltzer H, Cosyns P, **Calabrese JR**, D'Hondt P, Blockx P: Adrenocorticotrophic hormone, beta endorphin and cortisol responses to ovine CRH in unipolar depressed patients pretreated with dexamethasone. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 1994 Dec;18(8):1273-1292.
58. Bowden CL, **Calabrese JR**, Wallin BA, Swann AC, McElroy SL, Risch SC, Hirschfeld RM: Illness characteristics of patients in clinical drug studies of mania. *Psychopharmacology Bulletin* 1995;31(1):103-9.
59. **Calabrese JR**, Woysville MJ: A medication algorithm for treatment of bipolar rapid cycling. *J Clin Psychiatry* 1995;56(3):11-18.
60. Suppes T, **Calabrese JR**, Mitchell PB, Pazzaglia PJ, Potter WZ, Zarin DA: B. Algorithms for the treatment of bipolar, manic depressive illness. *Psychopharmacology Bulletin* 1995;31(3):469-74.
61. Maes M, Bosmans E, **Calabrese JR**, Smith R, Meltzer H: Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. *J of Psychiatric Research* 1995;2:141-152.
62. **Calabrese JR**, Woysville MJ: Lithium therapy: Limitations and alternatives in the treatment of bipolar disorder. *Annals of Psychiatry* 1995 Jun;7(2):103-112.
63. Maes M, Goossens F, Scharpe S, **Calabrese JR**, Desnyder R, Meltzer HY: Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: Effects of antidepressants, mood stabilizers, and antipsychotic drugs. *Psychiatry Research* 1995;58:217-225.
64. Fatemi S, **Calabrese JR**: Treatment of valproate-induced alopecia with zinc and selenium. *Annals of Pharmacotherapy* 1995 Dec;29(12):1302.
65. Petty F, Rush AJ, Davis JM, **Calabrese JR**, Kimmel SE, Small JG, Swann AE, Orsulak PJ, Bowden CL, Blake M, Morris D: Plasma GABA predicts acute response to divalproex in mania. *Biol Psychiatry* 1996 Feb;15;39(4):278-84.
66. **Calabrese JR**, Fatemi SH, Kujawa MJ, Woysville MJ: Predictors of response to mood stabilizers. *J Clin Psychopharmacology* 1996 Apr;16(2 Suppl 1):24S-31S.
67. **Calabrese JR**, Kimmel SE, Woysville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY: Clozapine in treatment refractory mania. *Am J Psychiatry* 1996 Jun;153(6):759-64.
68. Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, **Calabrese JR**, Goodnick P, Small JG, Rush J, Kimmel SE, Risch SC, Morris DD: Relationship of serum valproate concentration to response in mania. *Am J of Psychiatry* 1996 Jun;153(6):765-70.
69. **Calabrese JR**, Fatemi SH, Woysville MJ: Antidepressant Effects of Lamotrigine in Bipolar Rapid Cycling. *Am J Psychiatry* 1996 Sep;153(9):1236.
70. **Calabrese, JR**, Goethe JW, Kayser A, Marcotte DB, Monagin JA, Kimmel SE, Brugger AM, Morris D,

- Fatemi SH: Adverse events in 583 valproate-treated patients. *Depression* 1996;3:5:257-262.
71. Swann AC, Bowden CL, Morris D, **Calabrese JR**, Petty F, Small J, Dilsaver SC, Davis JM: Depression during mania: Treatment response to lithium or divalproex. *Arch Gen Psychiatry* 1997 Jan;54(1):37-42.
 72. Maes M, **Calabrese J**, Jayathilake K, Meltzer HY: Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: Evidence for increased central serotonergic neurotransmission. *Psychiatry Research* 1997;71:2:67-76.
 73. Fatemi SH, Rapport DJ, **Calabrese JR**, Thuras P: Lamotrigine in rapid-cycling bipolar disorder. *J Clin Psychiatry* 1997 Dec;58(12):522-7.
 74. Bowden C, Swann A, **Calabrese JR**, McElroy S, Morris D, Petty F, Hirschfeld R, Gyulai L: Maintenance clinical trials in bipolar disorder: Design implications of the divalproex-lithium placebo study. *Psychopharmacology Bulletin* 1997;33(4):693-9.
 75. Bowden CL, Davis J, Morris D, Swann A, **Calabrese JR**, Lambert M, Goodnick P: Effect size of efficacy measures comparing divalproex, lithium, and placebo in acute mania. *Depress Anxiety* 1997;6:26-30.
 76. **Calabrese JR**, Rapport DJ, Shelton MD, Kimmel SE: Clinical studies on the use of lamotrigine in bipolar disorder. *Neuropsychobiology* 1998 Oct;38(3):185-91.
 77. **Calabrese JR**, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD for the Lamictal 602 Study Group: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. *J Clin Psychiatry* 1999 Feb;60(2):79-88.
 78. **Calabrese JR**, Rapport DJ: Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. *J Clin Psychiatry* 1999;60 Suppl5:5-13; discussion 14-5.
 79. **Calabrese JR**, Rapport DJ, Shelton MD: Fish oils and bipolar disorder: Promising but untested. *Arch Gen Psychiatry* 1999 May;56(5):413-4; discussion 425-6.
 80. Bowden CL, **Calabrese JR**, McElroy SL, Rhodes LJ, Keck PE, Cookson J, Anderson J, Bolden-Watson C, Ascher J, Monaghan E, Ascher J: The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. *Biol Psychiatry*. 1999 Apr 15;45(8):953-8.
 81. **Calabrese JR**, Bowden CL, McElroy SL, Cookson J, Andersen J, Rhodes L, Keck PE, Bolden-Watson C, Zhou J, Ascher J: Spectrum of activity of lamotrigine in treatment refractory bipolar disorder. *Am J Psychiatry*. 1999 Jul;156(7):1019-23.
 82. Swann AC, **Calabrese JR**, Bowden JR, Dilsaver SC, Morris DD: Mania: Differential effect of number of previous depressive and manic episodes on response to treatment. *Am J Psychiatry* 1999 Aug;156(8):1264-6.
 83. **Calabrese JR**, Rapport DJ, Kimmel SE, Shelton MD: Controlled trials in bipolar I depression: Focus on switch rates and efficacy. *Eur. Neuropsychopharmacol.* 1999 Aug; 9 Suppl 4:S109-12. Review.
 84. **Calabrese JR**: Lamotrigine and the treatment of bipolar disorder. Introduction. *Eur. Neuropsychopharmacol.* 1999 Aug;9 Suppl 4:S107-8.

85. Swann AC, Petty F, Bowden CL, Dilsaver SC, **Calabrese JR**, Morris DD: Mania: Gender transmitter function, and response to treatment. *Psychiatry Res.* 1999 Oct;18;88(1):55-61.
86. Findling RL, Gracious BL, McNamara NK, **Calabrese JR**: The rationale, design, and progress of two novel maintenance treatment studies in pediatric bipolarity. *Bipolar Disorder. Acta Neuropsychiatrica* 2000;12:136-138.
87. Bowden CL, **Calabrese JR**, McElroy SL, Hirschfeld RMA, Petty F, Gyulai L, Pope HG, Chou JCY, Keck PE, Rhodes LJ, Swann AC, Wassef A, Wozniak PJ for the Divalproex Bipolar Study Group: A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. *Arch Gen Psychiatry.* 2000 May;57(5):481-9.
88. Swann AC, Bowden CL, **Calabrese JR**, Dilsaver SC, Morris DD: Mania: differential effects of previous depressive and manic episodes on response to treatment. *Acta Psychiatr. Scand.* 2000 Jun;101(6):444-51.
89. Shelton MD, **Calabrese JR**: Current concepts in rapid cycling bipolar disorder. *Cur Psychiatry Rep.* 2000 Aug;2(4):310-5.
90. Findling RL, **Calabrese JR**: Rapid Cycling Bipolar Disorder in Children. *Am J Psychiatry* 2000 Sep;157(9): 1526-7.
91. **Calabrese JR**, Gajwani P: Lamotrigine and clozapine for bipolar disorder. *Am J Psychiatry.* 2000 Sep;157(9):1523.
92. Keck PE, Mendlwicz J, **Calabrese JR**, Fawcett J, Suppes T, Vestergaard PA: A review of randomized, controlled clinical trials in acute mania. *J Affect Disorder.* 2000 Sep;59 Suppl 1:S31-S37.
93. Young A, Macritchie KA, **Calabrese JR**: Pharmacologic Treatment for Bipolar Affective Disorder. New drug treatments are emerging, more clinical evidence is required. *British Medical Journal.* 2000 Nov 25;321(7272):1302-3.
94. **Calabrese JR**, Suppes T, Bowden CL, Kusumakar V, Sachs GS, Swann AC, McElroy SL, Ascher JA, Earl NL, Greene PL, Monaghan ET for the Lamictal 614 Study Group: A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder. *J Clin Psychiatry.* 2000 Nov;61(11):841-50.
95. Hirschfeld RMA, Williams JBW, Spitzer RL, **Calabrese JR**, Flynn L, Keck PE, Lewis L, McElroy SL, Post RM, Rapport DJ, Russell JM, Sachs GS, Zajecka J: Development & validation of a screening instrument for bipolar spectrum disorder: The mood disorders questionnaire. *Am J Psychiatry* 2000 Nov;157(11):1873-5.
96. **Calabrese JR**, Keck PE, McElroy SL, Shelton MD: Pilot study of topiramate as monotherapy in acute mania. *J Clin Psychopharmacology.* 2001 Jun;21:340-2.
97. **Calabrese JR**, Rapport DJ, Shelton MD, Kimmel SE: Evolving methodologies in bipolar maintenance research. *Br J Psychiatry.* 2001 Jun;41:s157-63.
98. Youngstrom EA, Findling RL, Danielson CK, **Calabrese JR**: Discriminant validity of parent report of

- hypomanic and depressive symptoms on the General Behavioral Inventory. *Psychol. Assess.* 2001 Jun;13(2):267-76.
99. **Calabrese JR**, Shelton MD, Bowden CL, Rapport DJ, Suppes T, Shirley ER, Kimmel SE, Caban S: Bipolar rapid cycling: Focus on depression as its hallmark. *J Clin Psychiatry* 2001;62:34-41. { cited by 80 }
100. Findling RL, Gracious BL, McNamara NK, Youngstrom EA, Demeter CA, Branicky LA, **Calabrese JR**: Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. *Bipolar Disorders.* 2001 Aug;3(4):202-10.
101. Swann AC, Janicak P, **Calabrese JR**, Bowden CL, Dilsaver S, Morris DD, Petty F, Davis J: Structure of mania: Depressive, irritable, and psychotic clusters with distinct course of illness in randomized clinical trial participants. *J Affect Disord.* 2001 Dec;67(1-3):123-32.
102. Tohen M, Chengappa KNR, Suppes TR, Zarate CA, **Calabrese JR**, Bowden CL, Sachs GS, Kupfer D, Baker R, Risperidone RC, Keeter EL, Feldman PD, Tollefson GD, Breier A: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially non-responsive to valproate or lithium monotherapy. *Arch Gen Psychiatry.* 2002 Jan;59(1):62-9.
103. **Calabrese JR**, Shelton MD, Rapport DJ, Kujawa M, Kimmel SE, Caban S: Current research on rapid cycling bipolar disorder and its treatment. *J Affect Disord.* 2001 Dec;67(1-3):241-55.
104. **Calabrese JR**, Shelton MD, Rapport DJ, Kimmel SE: Bipolar disorders and the effectiveness of novel anticonvulsants. *J Clin Psychiatry* 2002;63 Suppl 3:5-9.
105. Ketter TA, **Calabrese JR**: Stabilization of mood from below versus above baseline in bipolar disorder: A new nomenclature. *J Clin Psychiatry.* 2002 Feb;63(2):146-151. { cited by 66 }
106. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Moller H-J, for the WFSBP Task Force (Calabrese included) on Treatment Guidelines for Bipolar Disorders. *World J Biol Psychiatry* 2002;3:115-124.
107. Swann AC, Bowden CL, **Calabrese JR**, Dilsaver SC, Morris DD: Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. *Neuropsychopharmacology* 2002 Apr;26(4):530-6.
108. Suppes T, Dennehy EB, Swann AC, Bowden CL, **Calabrese JR**, Hirschfeld R, Keck PE, Sachs G, Crismon ML, Toprac M, Shon SP. Report of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. *J Clin Psychiatry* 2002 Apr;63(4):288-299. { cited by 67 }
109. Yatham LN, Kusumakar V, **Calabrese JR**, Rao R, Scarrow G, Kroeker G: Third generation anticonvulsants in bipolar disorder: Review of efficacy and summary of clinical recommendations. *J Clin Psychiatry.* 2002 Apr;63(4):275-83.
110. Findling RL, Youngstrom EA, Danielson CK, DelPorto-Bedoya D, Papish-David R, Townsend L, **Calabrese JR**: Clinical decision-making using the general behavior inventory in juvenile bipolarity. *Bipolar Disorders* 2002 Febr;4(1):34-42.
111. Muzina DJ, El-Sayegh S, **Calabrese JR**: Antiepileptic drugs in psychiatry – focus on randomized

- controlled trials. *Epilepsy Research* 2002 Jun;50(1-2):195-202.
112. **Calabrese JR**, Shelton MD, Rapport DJ, Kimmel SE, Elhaj O: Long-term treatment of bipolar disorder with lamotrigine. *J Clin Psychiatry* 2002;63[Suppl 10]:18-22.
 113. Youngstrom EA, Danielson CK, Findling RL, Gracious BL, **Calabrese JR**: Factor structure of the Young Mania Rating Scale for use with youths aged 5 to 17 years. *J Clin Child and Adolesc. Psychology* 2002 Dec;31(4):567-72.
 114. Gracious BL, Youngstrom EA, Findling RL, **Calabrese JR**: Discriminative validity of a parent version of the Young Mania Rating Scale. *J Am Ac Child & Adel Psychiatry*. 2002 Nov;41(11):1350-9.
 115. **Calabrese JR**, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs G, Shelton M, Goodwin FK, Frye MA, Kusumakar V: Rash in multicenter trials of lamotrigine in mood disorder: Clinical relevance and management. *J Clin Psychiatry* 2002 Nov;63(11): 1012-1019. {cited by 79}
 116. Hirschfeld RMA, Holzer C, **Calabrese JR**, Weissman M, Reed M, Davies M, Frye MA, Keck P, McElroy S, Lewis L, Tierce J, Wagner KD, Hazard E: Validity of the Mood Disorders Questionnaire: A general population study. *J Clin Psychiatry*. 2003 Jan;160(1):178-80. {cited by 56}
 117. Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL, **Calabrese JR**, Feldman PD, Jacobs TG, Breier A: Olanzapine in the acute treatment of bipolar disorder with a history of rapid cycling. *J Affect Disord* 2003 Jan;73(1-2):155-61.
 118. Hirschfeld RMA, **Calabrese JR**, Weissman MM, Reed M, Davies MA, Frye MA, Keck PE Jr., Lewis L, McElroy SL, McNulty JP, Wagner KD: Screening for bipolar disorder in the community. *J Clin Psychiatry* 2003;64-53-59.
 119. Danielson CK, Youngstrom EA, Findling RL, **Calabrese JR**: Discriminant validity of the General Behavior Inventory Using Youth Report. *J Abnorm. Child Psychol*. 2003 Feb;31(1):29-39.
 120. Yatham LN, **Calabrese JR**, Kusumakar V: Bipolar depression: Criteria for treatment selection, definition of refractoriness, and treatment options. *Bipolar Disorders*. 2003 Apr;5(2):85-97.
 121. Bowden CL, **Calabrese JR**, Sachs G, Yatham LN, Akthar-Asghar S, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeugh-Geiss J for the Lamictal 606 Study Group: A placebo-controlled 18 month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. *Arch Gen Psychiatry*. 2003 Apr;60(4):392-400.
 122. **Calabrese JR**, Hirschfeld RMA, Reed M, Davies MA, Frye MA, Keck PE, Jr., Lewis L, McElroy SL, McNulty JP, Wagner KD: Impact of bipolar disorder on a U.S. community sample. *J Clin Psychiatry*. 2003 April;64(4):425-432. {cited by 60}
 123. **Calabrese JR**, Londborg P, Shelton MD, Shelton MD: Citalopram treatment of fluoxetine intolerant depressed patients. *J Clin Psychiatry*. 2003 May;64(5):562-567.
 124. Youngstrom EA, Findling RL, **Calabrese JR**: Who are the comorbid Adolescents? Agreement between psychiatric diagnosis, youth, parent, and teacher report. *J Abnorm. Child Psychol*. 2003 Jun;31(3):231-45.

125. Gyulai L, Bowden CL, McElroy SL, **Calabrese JR**, Petty F, Swann AC, Chou JCY, Wassef A, Risch CS, Hirschfeld RMA, Nemeroff C, Keck PE, Wozniak PJ: Maintenance efficacy of divalproex in the prevention of bipolar depression. *Neuropsychopharmacology*. 2003 July; 28(7): 1377-85. {cited by 78}
126. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, **Calabrese J**, Kupfer D, Rosenbaum JF: Rationale, design, and methods of the systematic enhancement program for bipolar disorder (STEP-BD). *Biol Psychiatry*. 2003 Jun 1;53(11):1028-42.
127. Carlson GA, Jensen PS, Findling RL, Meyer RE, **Calabrese J**, del Bello M, Emslie G, Flynn L, Goodwin F, Hellander M, Kowatch R, Kusumakar V, Laughren T, Leibenluft E, McCracken J, Nottelmann E, Pine D, Sachs G, Shaffer D, Simar R, Strober M, Weller E, Wozniak J, Youngstrom E: Methodological issues and controversies in clinical trials with child and adolescent patients with bipolar disorder: Report of a Consensus Conference. *J Child Adolesc. Psychopharmacol*. 2003 Spring;13(1):13-27.
128. Findling RL, McNamara NK, Gracious BL, Youngstrom EA, Stansbrey RJ, Reed MD, Demeter CA, Branicky LA, Fisher KE, **Calabrese JR**: Combination lithium and divalproex sodium in pediatric bipolarity. *J Am Acad. Child Adolesc. Psychiatry*. 2003 Aug;42(8):895-901. {cited by 59}
129. Baldessarini RJ, Hennen J, Wilson M, **Calabrese J**, Chengappa R, Keck Jr. PE, McElroy SL, Sachs G, Vieta E, Welge JA, Yatham LN, Zarate Jr. CA, Baker RW, Tohen M: Olanzapine vs. placebo in acute mania: Treatment responses in subgroups. *J Clin Psychopharmacology* 2003;23(4): 370-76.
130. **Calabrese JR**, Vieta E, Shelton MD: Latest maintenance data on lamotrigine in bipolar disorder. *European Neuropsychopharmacology*. 2003; August 13(2):S57-66.
131. Muzina D, **Calabrese JR**: Recent-placebo-controlled acute trials of bipolar depression: Focus on methodology. *Int. J Neuropsychopharmacol*. 2003 Sep;6(3):285-91.
132. Youngstrom EA, Gracious BL, Danielson CK, Findling RL, **Calabrese JR**: Toward an integration of parent and clinician report on the Young Mania Rating Scale. *J Affective Disorders*. 2003;77(2):179-90.
133. Tohen M, Vieta E, **Calabrese J**, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. *Arch Gen Psychiatry* 2003 Nov;60(11):1079-88. Erratum in: *Arch Gen Psychiatry* 2004 Febr;61(2):176.
134. **Calabrese JR**, Bowden CL, Sachs G, Yatham L, Behnke K, Mehtonen O-P, Montgomery P, Ascher J, Paska W, Earl NL, DeVeugh-Geiss J, for the Lamictal 605 Study Group: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder [Comment in: *Evid. Based Ment. Health* 2004;7:48] *J Clin Psychiatry*. 2003 Sept;64(9):1013-1024.
135. Toichi M, Findling RL, Kubota Y, **Calabrese JR**, Wiznitzer M, McNamara NK, Yamamoto Hemodyanmic differences in the activation of the prefrontal cortex: attention vs. higher cognitive processing. *Neuropsychologia*.. 2004;42(5):698-706.
136. Gracious BL, Findling RL, Seman C, Youngstrom EA, Demeter CA, **Calabrese JR**: Elevated TSH in bipolar youth prescribed both lithium and divalproex sodium. *J Am. Ac. Child Psychiatry*. 2004

Feb;43(2):215-220.

137. Kahana SY, Youngstrom EA, Findling RL, **Calabrese JR**: Employing parent, teacher, and youth self-report checklists in Identifying pediatric bipolar spectrum disorders: An examination of diagnostic accuracy and clinical utility. *J Child Adolescent Psychopharmacology*. 2003 Winter;13(4):471-88.
138. Marangell LB, Martinez JM, Ketter TA, Bowden CL, Goldberg JF, **Calabrese JR**, Miyahara S, Miklowitz DJ, Sachs GS, Thase ME; STEP-BD Investigators: Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. *Bipolar Disorders*. 2004 April;6(2): 139-143.
139. Tohen M, Chengappa KNR, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evants AR, **Calabrese JR**: Prevention of recurrence of bipolar I disorder in patients responsive to treatment with olanzapine combined with lithium or valproate: An 18-month comparison of continued combination treatment versus lithium or valproate monotherapy. *Br J Psychiatry*. 2004 April 184(4):337-45.
140. Goodwin GM, Bowden CL, **Calabrese JR**, Grunze H, Kasper S, White R, Greene P, Leadbetter R: A pooled analysis of two placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. *J Clin Psychiatry*. 2004 Mar;65(3):432-41.
141. **Calabrese JR**, Kasper S, Johnson G, Tajima O, Vieta E, Yatham LN, Young A: International consensus group on bipolar I depression treatment guidelines. *J Clin Psychiatry*. 2004 April;65(4):571-9. Review.
142. **Calabrese JR**: Depression mood stabilization: novel concepts and clinical management. *Eur Neuropsychopharmacol*. 2004 May: 14 Suppl 2:S100-7.
143. Youngstrom EA, Findling RL, **Calabrese JR**, Gracious BL, Demeter C, DelPorto-Bedoya D, Price M: Comparing the diagnostic accuracy of six potential screening instruments for bipolar disorder in youths aged 5 to 17 years. *J Am Acad. Child Adolesc. Psychiatry*. 2004 Jul;43(7):847-858.
144. Swann AC, Daniel D, Kochan L, Wozniak P, **Calabrese JR**: Psychosis in mania: Specificity of its role in severity and treatment response. *J Clin Psychiatry*. 2004 Jun;65(6):825-829.
145. Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E, Nierenberg AA, **Calabrese JR**, Sachs GS, Pollack MH for the STEP-BD Investigators: Pharmacotherapy for bipolar disorder and comorbid conditions: Baseline data from STEP BD. *J Clin Psychopharmacology*. 2004 Oct;24(5):512-20.
146. Schneck CD, Miklowitz DJ, **Calabrese JR**, Allen MH, Thomas MR, Wisniewski SR, Miyahara S, Shelton MD, Ketter TA, Goldberg JF, Bowden CL, Sachs GS: Phenomenology of rapid cycling bipolar disorder: Data from the first 500 participants in the Systematic treatment enhancement program for bipolar disorder. *Am J Psychiatry*. 2004 Oct;161(10):1902-8.
147. Vieta E, **Calabrese J**, Tohen M, Yatham L, Hennen, Colom F, Martinez-Aran A, Baldessarini R: Short and long-term outcome of rapid versus non-rapid cycling bipolar I patients treated with olanzapine. *J Clin Psychiatry*. 2004 Oct;65(10):1420-8.
148. Post RM, **Calabrese JR**: Bipolar depression: the role of atypical antipsychotics. *Expert Rev Neurother*. 2004 Nov;4(6 Suppl 2):S27-33.

149. Kogan JN, Otto MW, Bauer MS, Dennehy EB, Miklowitz DJ, Zhang HW, Ketter T, Rudorfer MV, Wisniewski SR, Thase ME, **Calabrese J**, Sachs GS for the STEP-BD Investigators: Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Bipolar Disorders*. 2004 Dec;6(6):460-9.
150. **Calabrese JR**, Hirschfeld RMA, Frye MA, Reed ML: Impact of depressive symptoms compared with manic symptoms in bipolar disorder: Results of a U.S. community-based sample. *J Clin Psychiatry* 2004 Nov;65(11):1499-1504.
151. O'Brien CP, Charney DS, Lewis L, Cornish JW, Post RM, Woody GE, Zubieta J-K, Blaine JD, Bowden CL, **Calabrese JR**, Carroll K, Childress AR, Davis MA, DeMartino R, Drake RE, Fleming MF, Fricks L, Glassman AH, Johnson RL, Jordan C, Kessler RC, Kosten T, Laden SK, Levin FR, Nunes EV, Oslin DW, Pettinati H, Regier DA, Renner JA, Ries RK, Rounsaville B, Sklar-Blake T, Weisner C: Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: A call to action. *Biological Psychiatry*. 2004 Nov 15;56(10):703-13.
152. Youngstrom EA, Findling RL, **Calabrese JR**: Effects of adolescent manic symptoms on agreement between youth, parent, and teacher ratings of behavior problems. *J Affect. Disord.* 2004 Oct; 82:Suppl 1:S5-S16.
153. Baker RW, Brown E, Akiskal HS, **Calabrese JR**, Ketter TA, Schuh LM, Trzepacz PT, Watkin JG, Tohen M: Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. *Br J Psychiatry* 2004 Dec;185:472-8.
154. **Calabrese JR**, Vieta E, El-Mallakh R, Findling RL, Youngstrom EA, Elhaj O, Gajwani P, Pies R: Mood state at study entry as predictor of risk of relapse and spectrum of efficacy in bipolar maintenance studies. *Biol Psychiatry*. 2004 Dec 15;56(12):957-73.
155. Papadimitriou GN, **Calabrese JR**, Dikeos DG, Christodoulou GN: Rapid cycling bipolar disorder: biology and pathogenesis. *Int. J Neuropsychopharmacol.* 2005 Jun;8(2):281-92.
156. **Calabrese JR**, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Findling RL: New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder. *Eur. Psychiatry* 2005 Mar;20(2):92-5.
157. Singh V, Muzina DJ, **Calabrese JR**: Anticonvulsants in bipolar disorder. *Psychiatric Clinics of North America* 2005 Apr;28(2):301-23.
158. Muzina DJ, Elhaj O, Gajwani P, Gao K, **Calabrese JR**. Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. *Acta Psychiatr. Scand* 2005: 111 (426): 21-28.
159. Findling RL, McNamara NK, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD, **Calabrese JR**: Double-blind, 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. *J Am Ac Child & Adolesc. Psychiatry.* 2005 May;44(5):409-17.
160. Sajatovic M, Gyulai L, **Calabrese JR**, Thompson TR, Wilson BG, White R, Evoniuk G: Maintenance treatment outcomes in older patients with bipolar I disorder. *Am J Geriatric Psychiatry* 2005 Apr;13(4):305-11.
161. Weiss RD, Ostacher M, Otto MW, **Calabrese J**, Fossey M, Wisniewski SR, Bowden C, Nierenberg

- AA, Pollack MH, Salloum I, Simon NM, Thase ME, Sachs GS: Recovery from substance use disorder in patients with bipolar disorder: Does it matter? *J Clin Psychiatry*. *J Clin Psychiatry* 2005 Jun;66(6):730-5.
162. Bowden CL, Collins MA, McElroy SL, **Calabrese JR**, Swann AC, Weisler RH, Wozniak PJ: Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. *Neuropsychopharmacology*. 2005 Oct;30(10):1932-9.
163. **Calabrese JR**, Keck PE, Jr., Macfadden W, Minkwitz M, Ketter TA, Weisler RG, Cutler AJ, McCoy R, Wilson E, Mullen J, for the Bolder Study Group: A randomized, double-blind, placebo-controlled trial of quetiapine, in the treatment of bipolar I or II depression. *Am J Psychiatry*. 2005 July;162(7):1351-1360.
164. Tohen M, Greil W, **Calabrese JR**, Sachs G, Yatham LN, Muller Oerlinghausen B, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL: Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical Trial. *Am J Psychiatry*. 2005 Jul;162(7):1281-1290.
165. Gajwani P, Forsthoef A, Muzina D, Amann B, Gao K, Elhaj O, **Calabrese JR**, Grunze H: Antiepileptic drugs in mood disordered patients. *Epilepsia* 2005;46 Suppl 4:38-44.
166. Hatters-Friedman S, Shelton MD, Elhaj O, Youngstrom EA, Rapport DJ, Packer K, Bilali SR, Jackson KS, Sakai HE, Resnick PJ, Findling RL, **Calabrese JR**: Gender differences in criminality: Dual diagnosis bipolar disorder. *J Am Acad. Psychiatry Law*. 2005;33(2):188-95.
167. Kubota Y, Toichi M, Shimizu M, Mason RA, Coconcea C, Findling, RL, Yamamoto K, **Calabrese JR**: Prefrontal activation during verbal fluency tests in schizophrenia – a near infrared spectroscopy (NIRS) study. *Schizophr. Res* 2005 Sep 1(77):65-73.
168. Suppes T, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, **Calabrese JR**, Crisman ML, Ketter T, Sachs G, Swann AC: The Texas Implementation of Medication Algorithms: Update to the Algorithms for Treatment of Bipolar I Disorder. *J Clin Psychiatry*. 2005 Jul;66(7):870-886. { cited by 73 }
169. Youngstrom EA, Findling RL, Kogos Youngstrom J, **Calabrese JR**: Towards an evidence-based assessment of pediatric bipolar disorder. *J Clin Child & Adolesc. Psychol*. 2005 Sep;34(3):433-48
170. Hardoy MC, Garofalo A, Carpiello B, **Calabrese JR**, Carta MG: Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder. *Clin Pract. Epidemiol. Ment. Health* 2005 Jul 18;1(1):7.
171. Hardoy MC, Cadeddu M, Murru A, Carpiello B, Dell'Osso B, Mororsini PL, **Calabrese JR**, Carta MG. Validation of the Italian version of the "Mood Disorder Questionnaire" for the screening of bipolar disorders. *Clin Pract. Epidemiol. Ment. Health* 2005 Jul 18;1:8.
172. Muzina D, **Calabrese JR**: Maintenance Therapies in Bipolar Disorder: Focus on Randomized Controlled Trials. *Australian N Z J Psychiatry* 2005 Aug;39(8):652-61.
173. Gao K, **Calabrese JR**: Newer treatment studies for bipolar depression. *Bipolar Disorders* 2005 Dec; 7

Suppl 5:13-23.

174. **Calabrese JR**, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Ganocy SJ, Findling, RL: A 20-month, double-blind, maintenance trial of lithium vs. divalproex in rapid-cycling bipolar disorder. *Am J Psychiatry*. 2005 Nov;162:2152-2161. {cited by 37}
175. Gao K, Gajwani P, Elhaj O, **Calabrese JR**: Typical and atypical antipsychotics in bipolar depression. *J Clin Psychiatry*. 2005 Nov;66(11):1376-1385.
176. Frye MA, **Calabrese JR**, Reed M, Weissman MM, Wagner KD, Lewis L, McNulty J, Hirschfeld RMA: Bipolar disorder in the United States: Patterns of consultation, diagnosis and treatment in a population-based study. *Psychiatric Services*. 2005 Dec;56(12):1529-1533.
177. Mansour HA, Talkowski ME, Wood J, Bamne M, Chowdari KV, Allen M, Bowden CL, **Calabrese J**, El-Mallakh RS, Fagiolini A, Fossey MD, Friedman E, Gyulai L, Hauser P, Loftis J, Marangell L, Miklowitz D, Nierenberg AA, Patel J, Sachs G, Smoller J, Thase M, Frank E, Kupfer DJ, Nimgaonkar VL: Serotonin Gene Polymorphisms and Bipolar I Disorder: Focus on the Serotonin Transporter. *Annals of Medicine*. 2005 Dec 1;37(8):590-602.
178. Goldberg JF, Allen MH, Miklowitz DA, Bowden CL, Endick CJ, Chessick CA, Wisniewski SR, Miyahara S, Sagduyu K, Thase ME, **Calabrese JR**, Sachs GS: Suicidal Ideation and pharmacotherapy among STEP-BD patients. *Psychiatr. Serv*. 2005 Dec;56(12):1534-1540.
179. Findling RL, Youngstrom EA, McNamara NK, Stansbrey RS, Demeter CA, Bedoya D, Kahana SY, **Calabrese JR**: Early symptoms of mania and the role of parental risk. *Bipolar Disorders*. 2005 Dec;7(6):623-34.
180. Youngstrom EA, Meyers O, Demeter C, Youngstrom J, Morello Simonitis L, Piiparinen R, Feeny N, **Calabrese JR**, Findling RL: Comparing diagnostic checklists for pediatric bipolar disorder in academic and community mental health settings. *Bipolar Disorders*. 2005 Dec;7(6):507-17.
181. Allen MH, Chessick CA, Miklowitz DJ, Goldberg JF, Wisniewski SR, Miyahara S, **Calabrese JR**, Marangell L, Bauer MS, Thomas MR, Bowden CL, Sachs GS: Contributors to suicidal ideation among bipolar patients with and without a history of suicide attempts. *Suicide and Life-Threatening Behavior*. 2005 Dec;35(6):671-680.
182. Shimizu M, Kubota Y, **Calabrese JR**, Toichi M, Kato S, Baba H: Analysis of delusional statements from 15 Japanese cases of 'Folie a Deux'. *Psychopathology*. 2006 Jan 2;39(2):92-98.
183. Findling RL, McNamara NK, Stansbrey R, gracious BL, Whipkey RE, Demeter CA, Youngstrom EA, **Calabrese JR**: Combination lithium and divalproex sodium in pediatric bipolar symptom restabilization. *J Am Acad. Child Adolesc. Psychiatry* 2006 Feb;45(2):142-148.
184. Nierenberg AA, Ostacher MJ, **Calabrese JR**, Ketter TA, Marangell L, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS for the STEP-BD Investigators: Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol or risperidone. *Am J Psychiatry*. 2006 Feb;163(2):210-16.
185. Tohen M, **Calabrese JR**, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JCY, Bowden CL: A Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients with

- Bipolar I Disorder Responding to Acute Olanzapine Treatment. *Am J Psychiatry*. 2006 Feb;163(2):247-56.
186. Sachs G, Bowden C, **Calabrese J**, Ketter T, Thompson T, White R, Powers C, Bentley B: Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. *Bipolar Disord* 2006 Apr;8(2):175-81.
187. Keck PE Jr., **Calabrese JR**, McQuade RD, Carson W, Carlson BX, Rolling LM, Marcus RN, Sanchez R, and the Aripiprazole Study Group: A Placebo-controlled, 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. *J Clin Psychiatry*. 2006 Apr;67(4):626-637.
188. **Calabrese JR**, Goldberg JF, Ketter TA, Suppes T, Frye M, White, Robin; DeVeugh-Geiss A; Thompson TR: Recurrence in bipolar I disorder: A post hoc analysis excluding relapses in two double-blind maintenance studies. *Biol. Psychiatry* 2006 June 1:59(11):1061-4.
189. Wolff N, Perlick DA, Kaczynski R, **Calabrese J**, Nierenberg A, Miklowitz DJ: Modeling costs and burden of informal caregiving for persons with bipolar disorder. *J Ment. Health Policy Econ*. 2006 Jun;9(2):99-110.
190. Gajwani P, Muzina D, Gao K, **Calabrese JR**: Awareness under anesthesia during electroconvulsive therapy treatment. *J ECT* 2006 Jun;22(2):158-159.
191. Kubota Y, Toichi M, Shimizu M, Mason RA, Findling RL, Yamamoto K, **Calabrese JR**: Prefrontal hemodynamic activity predicts false memory – A near-infrared spectroscopy study. *Neuroimage*. 2006 July 15;31(4):1783-9.
192. Bowden CL, **Calabrese J**, Ketter TA, Sachs GS, White RL, Thompson TR: Impact of lamotrigine and lithium in obese and non-obese patients with bipolar I disorder. *Am J Psychiatry*. 2006 July;163(7):1199-201.
193. Youngstrom EA, Meyers OI, Youngstrom JK, **Calabrese JR**, Findling RL: Diagnostic and Measurement Issues in the Assessment of Pediatric Bipolar Disorder: Implications for Understanding Mood Disorder Across the Life Cycle. *Dev Psychopathol*. 2006 Fall;18:989-1021.
194. Marangell LB, Suppes T, Ketter TA, Dennehy EB, Zboyan H, Kertz B, Nierenberg A, **Calabrese J**, Wisniewski SR, Sachs G: Omega-3 fatty acids in bipolar disorder: Clinical and Research Considerations. *Prostaglandins Leukot. Essential Fatty Acids*. 2006 Oct-Nov;75(4-5):315-21.
195. Frye MA, **Calabrese JR**, Reed ML, Hirschfeld RM: Health care resource utilization in bipolar depression compared with unipolar depression: results of a US population-based study. *CNS Spectr*. 2006 Sep;11(9):704-10.
196. Bowden CL, Swann AC, **Calabrese JR**, Rubenfaer LM, Wozniak PJ, Hollines MA, Abi-Saab W, Saltarelli M for the Depakote ER Mania Study Group: A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of mania. *J Clin. Psychiatry* 2006 Oct;67(10):1501-1510.
197. Gao K, Muzina D, Gajwani P, **Calabrese JR**: Efficacy of Typical and Atypical Antipsychotics for Primary and Comorbid Anxiety Symptoms or Disorders: A Review. *J Clin Psychiatry* 2006 Sep;67(9):1327-1340.

198. Youngstrom EA, Meyers O, Kogos Youngstrom J, **Calabrese JR**, Findling RL: Comparing the effects of sampling designs on the diagnostic accuracy of eight promising screening instruments for pediatric bipolar disorder. *Biological Psychiatry*. 2006 Nov 1;60(9):1013-9.
199. Gajwani P, Kemp DE, Muzina DJ, Xia G, Gao K, **Calabrese JR**: Acute treatment of mania: An update on new medications. *Current Psychiatry Reports* 2006 Dec;8(6):504-9.
200. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, **Calabrese JR**; for the BOLDER II Study Group: Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, Placebo-controlled study (The BOLDER II Study). *J Clin Psychopharmacol* 2006 Dec;26(6):600-609. Erratum in: *J Clin Psychopharmacol*. 2007 Feb;27(1):51.
201. Tohen M, Bowden CL, **Calabrese JR**, Lin D, Forrester TD, Sachs GS, Koukopoulos A, Yatham L, Grunze H: Influence of sub-syndromal symptoms after remission from manic or mixed episodes. *Br J Psychiatry* 2006 Dec;189:515-9.
202. Shim SS, Hammonds MD, Ganocy SJ, **Calabrese JR**: Effects of sub-chronic lithium treatment on synaptic plasticity in the dentate gyrus of rat hippocampal slices. *Prog. Neuropsychopharmacol Biol Psychiatry* 2007 Mar 30;31(2):343-7.
203. Wang PW, Sachs GS, Zarate CA, Marangell LB, **Calabrese JR**, Goldberg JF, Sagduyu K, Miyahara S, Ketter TA: Overweight and obesity in bipolar disorder. *J Psychiatr. Res.* 2006 Dec;40(8):762-4.
204. Frye MA, Yatham LN, **Calabrese JR**, Bowden CL, Ketter TA, Suppes T, Adams BE, Thompson TR: Incidence and time course of sub-syndromal symptoms in patients with bipolar I disorder: An evaluation of two placebo-controlled maintenance trials. *J Clin Psychiatry*. 2006 Nov;67(11):1721-28.
205. Papadimitriou GN, Dikeos DG, Soldatos CR, **Calabrese JR**: Non-pharmacological treatments in the management of rapid cycling bipolar disorder. *J Affective Disorders*. 2007 Feb;98(1-2):1-10.
206. Muzina DJ, Colangelo E, Manning, **Calabrese JR**: Differentiating bipolar disorder from depression in primary care. *Cleve Clin J of Med*. 2007 Feb;74(2):89, 92, 95-9 passim.
207. Hammonds MD, Shim SS, Feng P, **Calabrese JR**: Effects of subchronic lithium treatment on levels of BDNF, Bcl-2 and phosphor-CREB in the rat hippocampus. *Basic Clin Pharmacol. Toxicol.* 2007 May;100(5):356-9.
208. Sachs GS, Nierenberg AA, **Calabrese JR**, Marangell LB, Wisniewski SR, Gyulai L, Friedman E, Bowden C, Fossey M, Ostacher M, Ketter T, Patel J, Hauser P, Rapport D, Martinez J, Allen M, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME: Effectiveness of adjunctive antidepressant treatment for bipolar depression: A double-blind placebo controlled study. *N Engl Journal Med*. 2007 Apr 26;356(17):1711-22. Epub 2007 Mar 28 {cited by 34}
209. Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Wisniewski SR, Kogan JN, Nierenberg AA, **Calabrese JR**, Marangell LB, Gyulai L, Araga M, Gonzalez JM, Shirley ER, Thase ME, Sachs GS: Psychosocial treatments for bipolar depression: A 1-year randomized trial from the Systematic Treatment Enhancement Program. *Arch Gen Psychiatry*. 2007 Apr;64(4):419-26.
210. Xia G, Gajwani P, Muzina DJ, Kemp DE, Gao K, Ganocy SJ, **Calabrese JR**: Treatment-emergent

- mania in unipolar and bipolar depression: Focus on repetitive transcranial magnetic stimulation. In *J Neuropsychopharmacol.* 2008 Feb;11(1):119-30. Epub 2007 Mar 5.
211. Findling RL, Frazier TW, Youngstrom EA, McNamara NK, Stansbrey RJ, Gracious BL, Reed MD, Demeter CA, **Calabrese JR**: Double-blind, placebo-controlled trial of Divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. *J Clinical Psychiatry* 2007 May;68(5):781-8.
212. Vieta E, **Calabrese JR**, Goikolea JM, Raines S, MacFadden W for the Bolder Study Group: Quetiapine monotherapy in the treatment of bipolar I or II depression and a rapid cycling course: A Randomized, Double-Blind, Placebo-Controlled Study. *Bipolar Disorders.* 2007 June;9(4):413-25.
213. Sajatovic, M, Elhaj O, Youngstrom EA, Bilali SR, Rapport DJ, Ganocy SJ, **Calabrese JR**: Treatment adherence in individuals with rapid cycling bipolar disorder – results from a clinical trial setting. *J Clin Psychopharmacology* 2007 Aug;27(4):412-14.
214. Tohen M, **Calabrese J**, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, Xu W, Coriza S: Effect of comorbid anxiety on treatment response in bipolar depression. *J Affective Disorders* 2007 Dec;104(1-3):137-46. Epub 2007 May 17.
215. Haro G, **Calabrese J**, Larsson C, Shirley E, Martin E, Leal C, Delgado P: Relationships between personality traits to substance abuse in patients with bipolar disorder. *Eur. Psychiatry.* 2007 Jul;22(5):305-8. Epub 2007 May 22.
216. Drotar D, Greenley RN, Demeter CA, McNamara NK, Stansbrey RJ, **Calabrese JR**, Vijay P, Findling RL: Adherence to pharmacological treatment for juvenile bipolar disorder. *J Child and Adolescent Psychiatry. J Am Acad. Child Adolesc. Psychiatry.* 2007 Jul;46(7):831-9.
217. Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Kogan JN, Sachs GS, Thase ME, **Calabrese JR**, Marangell LB, Ostacher MJ, Patel J, Thomas MR, Araga M, Gonzales JM, Wisniewski SR: Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. *Am J Psychiatry* 2007 Sept;164(9):1340-7.
218. Goldberg JF, Perlis RH, Ghaemi SN, **Calabrese JR**, Bowden CL, Araga M, Wisniewski S, Miklowitz DJ, Thase ME, Sachs GS, Thase M: Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: Findings from the STEP-BD. *Am J Psychiatry.* 2007 Sept;164(9)1348-55.
219. **Calabrese JR**, Guelfi JD, Perdrizet-Chevallier C, and the Agomelatine Bipolar Study Group: Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data. *Bipolar Disorders.* 2007 Sept;9(6):628-35.
220. Duax JM, Youngstrom EA, **Calabrese JR**, Findling RL: Sex differences in pediatric bipolar disorder. *J Clin Psychiatry* 2007 Oct;68(10):1565-73.
221. Sachs G, Nierenberg A, **Calabrese J**: Antidepressants are not an effective adjunct to mood stabilizers for bipolar depression. *Evid Based Ment Health* 2007 Nov;10(4):109.
222. Keck PE, **Calabrese JR**, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R for the Aripiprazole Study Group: Aripiprazole monotherapy for maintenance therapy in

- bipolar I disorder: A 100-week, double-blind study versus placebo. *J Clin Psychiatry*. 2007 Oct; 68 (10): 1480-91.
223. Findling RL, Short EJ, McNamara NK, Demeter CA, Stansbrey RJ, Gracious BL, Whipkey R, Manos MJ, **Calabrese JR**: Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention deficit/hyperactivity disorder. *J Am Ac Child and Adol Psychiatry* 2007 Nov;46(11):1445-53.
224. Hirschfeld RMA, **Calabrese J**, Frye MA, Lavori PW, Sachs G, Thase ME, Wagner K: Defining the clinical course of bipolar disorder: Response, remission, relapse, recurrence, and roughening. *Psychopharmacol Bull*. 2007;40(3):7-14.
225. McElroy SL, Bowden CL, Collins MA, Wozniak PJ, Keck PE, **Calabrese JR**: Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. *Journal of Affective Disorders*. 2008 Apr;107(1-3):127-33. Epub 2007 Sep 20.
226. Weisler RH, **Calabrese JR**, Bowden CL, Ascher JA, DeVeugh-Geiss J, Evoniuk G: Discovery and development of lamotrigine for bipolar disorder: A story of serendipity, clinical observations, risking taking, and persistence. *J Affect Disord*. 2008 May;108(1-2):1-9. Epub 2007 Nov 14. Review.
227. Miklowitz, D J, Otto MW, Frank E., Reilly-Harrington NA, Wisniewski SR, Kogan JN, Nierenberg AA, **Calabrese JR**, Marangell LB, Gyulai L, Araga M, Gonzalez JM, Shirley ER, Thase ME, Sachs GS. Is psychosocial management effective? In reply to Saddichha and Kumar. *Arch Gen Psychiatry*. 2007;64:1452-1453.
228. Sajatovic M, Jenkins JH, West JA, Meyer WJ, **Calabrese JR**: Personal and societal construction of illness among persons with rapid cycling bipolar disorder: A life trajectory perspective. *Am J Geriatric Psychiatry*. 2008 Sept;16(9):718-26. 2007 Dec 10; [Epub ahead of print].
229. Frazier TW, Demeter Ca, Youngstrom EA, **Calabrese JR**, Stansbrey RJ, McNamara NK, Findling RL: Evaluation and comparison of psychometric instruments for pediatric bipolar spectrum disorders. In four age groups. *J Child Adolesc. Psychopharmacocol*. 2007 Dec;17(6):853-66.
230. Goldberg JF, Bowden CL, **Calabrese JR**, Ketter TA, Dann RS, Frye MA, Suppes T, Post RM: Six-month prospective life charting of mood symptoms with Lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder. *Biol Psychiatry*. 2008 Jan 1;63(1):125-30. Epub 2007 Jun 1
231. Berk M, NG F, Wang WV, **Calabrese JR**, Mitchell PB, Malhi GS, Tohen M: The empirical redefinition of the psychometric criteria for remission in bipolar disorder. *Journal of Affective Disorders*. 2008 Feb;106(1-2):153-8. Epub 2007 Jul 26.
232. **Calabrese JR**, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan E, Leadbetter RA: Lamotrigine in the acute treatment of bipolar depression: Results of five double-blind, placebo-controlled clinical trials. *Bipolar Disord* 2008 Mar;10(2):323-333.
233. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, **Calabrese JR**: A review of the sensitivity and tolerability of patients with bipolar disorder or schizophrenia to antipsychotics: focus on somnolence. *J Clin Psychiatry*. 2008 Feb;69(2):302-9. Review.
234. Gao K, Tolliver B, Kemp DE, Verduin ML, Ganocy SJ, Bilali S, Brady K, Shim SS, Findling RL,

- Calabrese JR:** Differential interactions between comorbid anxiety disorders and substance use disorders in rapid cycling bipolar I or II disorder. *J Affect Disorders*. 2008 Sep;110(1-2):167-73. Epub 2008 Jan 29.
235. Kemp DE, Hirschfeld RM, Ganocy SJ, Elhaj O, Slembariski R, Bilali, R, Pontau J, Findling RL, **Calabrese JR:** Screening for bipolar disorder in a county jail at the time of criminal arrest. *J Psychiatric Research*. 2008 Jul;42(9):778-86. Epub 2007 Nov 1.
236. Du Rocher Schudlich TD, Youngstrom EA, **Calabrese JR**, Findling RL: The role of the family functioning in bipolar disorder in families. *J Abnorm Child Psych*. 2008 Aug;36(6):849-63. Epub 2008 Feb 13.
237. Pagano ME, Demeter CA, Faber JE, **Calabrese JR**, Findling RL: Initiation of stimulant and antidepressant medication and clinical presentations in bipolar I disorder. *Bipolar Disord* 2008 Mar;10(2):334-41.
238. Abraham PF, **Calabrese JR:** Evidenced-Based Pharmacologic Treatment of Borderline Personality Disorder: A Shift from SSRIs to Anticonvulsants and Atypical Antipsychotics?" Research Report in *Journal Affective Disorders*. 2008 Feb 25 [Epub ahead of print].
239. Altamura AC, Mundo E, Dell'Osso B, Tacchini G, Buoli M, **Calabrese JR:** Quetiapine and classical mood stabilizers in the long-term treatment of bipolar disorder: A 4-year follow-up naturalistic study. *J Affect Disord*. 2008 Sep;110(1-2):135-41. Epub 2008 Mar 10.
240. Gao K, Kemp DE, Gajwani P, Xia G, Ganocy SJ, **Calabrese JR:** Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A Systematic Review. *J Clin Psychopharmacology*. 2008;28(2):203-9. Review.
241. Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, Berman KF, Blair J, Braff DL, Brown ES, **Calabrese JR**, Carlezon WA Jr, Cook EH Jr, Davidson RJ, Davis M, Desimone R, Drevets WC, Duman RS, Essock SM, Faraone SV, Freedman R, Friston KJ, Gelernter J, Geller B, Gill M, Gould E, Grace AA, Grillon C, Gueorguieva R, Hariri AR, Innis RB, Jones EG, Kleinman JE, Koob GF, Krystal AD, Leibenluft E, Levinson DF, Levitt PR, Lewis DA, Liberzon I, Lipska BK, Marder SR, Markou A, Mason GF, McDougale CJ, McEwen BS, McMahan FJ, Meaney MJ, Meltzer HY, Merikangas KR, Meyer-Lindenberg A, Mirmics K, Monteggia LM, Neumeister A, O'Brien CP, Owen MJ, Pine DS, Rapoport JL, Rauch SL, Robbins TW, Rosenbaum JF, Rosenberg DR, Ross CA, Rush AJ, Sackeim HA, Sanacora G, Schatzberg AF, Shaham Y, Siever LJ, Sunderland T, Tecott LH, Thase ME, Todd RD, Weissman MM, Yehuda R, Yoshikawa T, Young EA, McCandless R: It is time to take a stand for medical research and against terrorism targeting medical scientists. *Biol Psychiatry*. 2008 Apr 15;63(8):725-7. Erratum in: *Biol Psychiatry*. 2008 May 15;63(10):1001.
242. Youngstrom EA, Frazier TW, Demeter C, **Calabrese JR**, Findling RL: Developing a 10-item mania scale from the parent General Behavior Inventory for children and adolescents. *J Clin Psychiatry* 2008 Apr 29:e1-e9. [Epub ahead of print].
243. Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B, Suppes T: Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: Combined results from two double-blind, randomized placebo-controlled studies. *J Clin*

- Psychiatry. 2008 69:769-82. Apr 29:e1-e14. [Epub ahead of print].
244. Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH, Chambert K, Nimgaonkar VL, McQueen MB, Faraone SV, Kirby A, de Bakker PI, Ogdie MN, Thase ME, Sachs GS, Todd-Brown K, Gabriel SB, Sougnez C, Gates C, Blumenstiel B, Defelice M, Ardlie KG, Franklin J, Muir WJ, McGhee KA, MacIntyre DJ, McLean A, VanBeck M, McQuillin A, Bass NJ, Robinson M, Lawrence J, Anjorin A, Curtis D, Scolnick EM, Daly MJ, Blackwood DH, Gurling HM, Purcell SM. **Collaborators:** Marangell LB, **Calabrese JR**, Nierenberg AA, Hauser P, Ketter TA, Thomas M, Patel J, Fossey MD, Gyulai L, Thase ME, Bowden CL, Molay F, Rosen-Sheidley B, Silfies L, Gejman PV, Sanders AR, Amin F, Buccola N, Byerley W, Cloninger CR, Crowe R, Black D, Freedman R, Levinson D, Mowry B, Silverman J, Nurnberger J, Miller MJ, Bowman ES, Rau NL, Moe PR, Samavedy N, El-Mallakh R, Manji H, Glitz DA, Meyer ET, Smiley C, Foroud T, Flury L, Dick DM, Edenberg H, Rice J, Reich T, Goate A, Bierut L, McInnis M, DePaulo JR Jr, MacKinnon DF, Mondimore FM, Potash JB, Zandi PP, Avramopoulos D, Payne J, Berrettini W, Byerley W, Vawter M, Coryell W, Crowe R, Gershon E, Badner J, McMahon F, Liu C, Sanders A, Caserta M, Dinwiddie S, Nguyen T, Harakal D, Kelsoe J, McKinney R, Scheftner W, Kravitz HM, Marta D, Vaughn-Brown A, Bederow L, McMahon FJ, Kassem L, Detera-Wadleigh S, Austin L, Murphy DL: Whole genome association study of bipolar disorder. *Mol Psychiatry*. 2008 Jun;13(6):558-69. Epub 2008 Mar 4.
245. Ostacher MJ, Nierenberg AA, Iosifescu DV, Eidelman P, Lunda HG, Ametrano RM, Kaczynski R, **Calabrese J**, Miklowitz DJ, Sachs G, Perlick DA, and the STEP-BD Family Experience Collaborative Study Group. Correlates of subjective and objective burden among caregivers of patients with bipolar disorder. *Acta Psychiatr Scand* 2008 Jul;118(1):49-56.
246. Gao K, Verduin ML, Kemp DE, Tolliver B, Ganocy SJ, Elhaj O, Bilali S, Brady K, Findling RL, **Calabrese JR**: Clinical correlates of patients with rapid cycling bipolar disorder and a recent history of substance use disorder: A subtype comparison from w randomized, placebo-controlled trials. *J Clin Psychiatry*. June 24,2008: e1-e7. [Epub ahead of print]
247. Nowakowska C, Sachs GS, Zarate CA, Marangell LB, **Calabrese JR**, Goldberg JF, Ketter TA: Increased rate of non-right handedness in patients with bipolar disorder. *J Clin Psychiatry*. 2008; May;69(5):866-7;
248. **Calabrese JR**: Overview of patient care issues and treatment in bipolar spectrum and bipolar II disorder. *J Clin Psychiatry*. 2008 Jun;69(6):e18.
249. Kemp DE, Muzina DJ, McIntyre RS, **Calabrese JR**: Bipolar depression: trial-based insights to guide patient care. *Dialogues Clin Neurosci* 2008;10(2):181-92.
250. Sajatovic M, **Calabrese JR**, Mullen J: Quetiapine for the treatment of bipolar mania in older adults. *Bipolar Disorders*. *Bipolar Disorders* 2008 Sep;10(6):662-671.
251. Muzina DJ, **Calabrese JR**: Reply to Dr. Eppel regarding 'Letter to the Editor. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. *Bipolar Disorders*. 2008 Sept;10(6):750-751.
252. Kubota Y, Toichi M, Shimizu M, Mason RA, Findling RL, Yamamoto K, Hayashi T, **Calabrese, JR**:

- Altered prefrontal lobe oxygenation in bipolar disorder – a study by near infrared spectroscopy. *Psychol Med* 2008 Sep 24;1-11 [Epub ahead of print].
253. **Calabrese JR**, Kemp DE: Bipolar Drug Development: Are We Getting Closer to the Real World? *Am J Psychiatry*. 2008 Oct;165(10): 1234-6.
254. Kasper S, **Calabrese JR**, Johnson G, Tajima O, Vieta E, Viguera AD, Yatham LN, Young AH: International Consensus Group on the Evidence-Based Pharmacologic Treatment of Bipolar I and II Depression. *J Clin Psychiatry* 2008 Oct;69(10):1632-1645.
255. Abraham PF, **Calabrese JR**: Evidence-based pharmacologic treatment of borderline personality disorder: A shift from selective serotonin reuptake inhibitors to anticonvulsants and atypical antipsychotics? *J Affective Disorders* 2008 Nov;111(1):21-30.
256. Kemp DE, Calabrese JR, Ismail-Beigi, F: Depressive symptoms and diabetes. *JAMA* 2008 Nov 12;300(18):2115-6; author reply 2116.
257. Abulseoud O, Hellman G, **Calabrese J**, Verduin M, Chirichigno J, McKowen J, Gitlin M, Altshuler L, Frye MA.: Gender and Bipolar Subtype Association with Self-Reported Hazardous Alcohol Consumption in Bipolar Depression. *J Dual Diagnosis* 2008, 4(3):291-302.
258. El-Mallakh RS, Ghaemi SN, Sagduyu K, Thase ME, Wisniewski SR, Nierenberg AA, Zhang HW, Pardo TA, Sachs G. Collaborators: Sachs GS, Thase ME, Leahy L, Kogan JN, Dennehy EB, Conley JA, Gradus JL, Gray SM, Flowers J, Graves M, Wisniewski S, Marangell LB, Martinez JM, **Calabrese JR**, Shelton M, Otto MW, Nierenberg AA, Lydiard RB, Goldberg JF, Chou JC, Cohen J, Zajecka J, Ketter TA, Wang PW, Halbreich U, Gelenberg A, Rapaport M, Thomas M, Allen MH, Miklowitz DJ, El-Mallakh RS, Patel J, Sagduyu K, Fossey MD, Yates WR, Gyulai L, Baldassano C, Friedman ES, Hauser P, Bowden CL, Gonzales CL, Bauer MS, Calabrese JR, Conley J, Dennehy EB, Fava M, Gottlieb G, Frank E, Ketter TA, Kogan JN, Kupfer D, Leahy L, Marangell LB, Miklowitz DJ, Otto MW, Rosenbaum J, Rudorfer MV, Street L, Ward S, Wisniewski S, Severe J.: Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. *J Affect Disord*. 2008 Dec;111(2-3):372-7. Epub 2008 Jun 20.
259. Kemp DE, Gao K, Ganocy SJ, Caldes E, Feldman K, Chan PK, Conroy C, Bilali S, Flindling RL, **Calabrese JR**: Medical and substance use comorbidity in bipolar disorder. *J Affect Disord*. 2009 Jul;116(1-2):64-9. Epub 2008 Dec 18.
260. Findling RL, Lingler J, Rowles BM, McNamara NK, **Calabrese JR**: A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. *J Child Adol Psychopharmacology* 2008;18(6)615-21.
261. Gao K, Kemp DE, Ganocy SJ, Muzina DJ, Xia G, Findling RL, **Calabrese JR**: Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. *Bipolar Disorders*. 2008;10:907-15.
262. Severus WE, Kleindienst N, Evoniuk G, Bowden C, Moller HJ, Bohus M, Fangou S, Greil W, **Calabrese JR**: Is the polarity of relapse/recurrence in Bipolar I Disorder patients related to serum lithium level? Results from an empirical study. *J Affect Disord* 2009 Jun;115(3):466-70. Epub 2008 Nov 20.

263. Tohen M, Sutton VK, **Calabrese JR**, Sachs GS, Bowden CL: Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double blind, placebo-controlled study of bipolar I disorder. 2009 Jul;116(1-2):43-50. Epub 2008 Dec 2.
264. Kemp DE, Gao K, Ganocy SJ, Rapport DJ, Elhaj O, Bilali S, Conroy C, Findling RL, **Calabrese JR**: A 6-month , double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid cycling bipolar disorder and co-occurring substance abuse or dependence. *J Clin Psychiatry* 2009 Jan;70(1):113-21. Epub 2008 Dec 30.
265. Geddes JR, **Calabrese JR**, Goodwin GM: Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from 5 randomized trials. *Br J Psychiatry*. 2009 Jan;194:4-9.
266. Fan J, Ionita-Laza I, McQueen MB, Devlin B, Purcell S, Faraone SV, Allen MH, Bowden CL, **Calabrese JR**, Fossey MD, Friedman ES, Gyulai L, Hauser P, Ketter T, Marangell LB, Miklowitz DJ, Nierenberg AA, Patel JK, Sachs GS, Thase ME, Molay FB, Escamilla MA, Nimgaonkar VL, Sklar P, Laird NM, Smoller JW: Linkage disequilibrium mapping of the chromosome 6q21-22.31 bipolar I disorder susceptibility locus. *Am J Med Genet Part B* 9999:1-9. *Neuropsychiatr Genet*. 2009 Mar 23. [Epub ahead of print]
267. Kemp DE, Ismail-Beige F, **Calabrese JR**: Antidepressant response associated with pioglitazone: Support for an overlapping pathophysiology between major depression and metabolic syndrome. *Am J Psychiatry* 2009 May;166(5):619.
268. Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, Marangell LB, **Calabrese JR**, Nierenberg AA, Sachs GS: Mania symptoms during depressive episodes in 1,380 patients with bipolar disorder: Findings from the STEP-BD. *Am J Psychiatry*. 2009;166:173-181. Jan 2. [Epub ahead of print]
269. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young T, Young AH, Alda M, Milev R, Vieta E, **Calabrese J**, Berk M, Ha K, Kapczinski F: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) Collaborative Update of CANMAT Guidelines for the Management of Patients with Bipolar Disorder: Update 2009. *Bipolar Disorders*. 2009;11(3):225-255.
270. Perlis RH, Dennehy EB, Miklowitz DJ, Delbello MP, Ostacher M, **Calabrese JR**, Ametrano RM, Wisniewski SR, Bowden CL, Thase ME, Nierenberg AA, Sachs G: Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. *Bipolar Disord* 2009 Jun;11(4):391-400.
271. Frye MA, Yatham L, Ketter TA, Goldberg J, Suppes T, **Calabrese JR**, Bowden CL, Bourne E, Bahn RS, Adams B: Depressive relapse during lithium treatment associated with increased serum TSH: Results from two placebo-controlled bipolar I maintenance studies. *Acta Psychiatr Scand* 2009 Jul;120(1):10-3. Epub 2009 Jan 31.
272. Tohen M, Frank E, Bowden CL, Colom F, Ghaemi NA, Yatham LN, Malhi GS, **Calabrese JR**, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KNR, Grunze H, Mitchell PB, Kanga S, Berk M: The International Society of Bipolar disorders (ISBD) Task Force on the Nomenclature of Course and Outcome in Bipolar Disorders. *Bipolar disorders*. 2009 Aug;11(5):453-73.

273. Gao K, Tolliver BK, Kemp DE, Ganocy SJ, Bilali S, Brady KL, Findling RL, **Calabrese JR**: Correlates of historical suicide attempt in rapid cycling bipolar disorder: A cross-sectional assessment. *J Clin Psychiatry*. 2009 Jul;70(7):1032-40.
274. Gao K, Sheehan DV, **Calabrese JR**: Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. *Expert Review of Neurotherapeutics*. 2009 Aug;9(8):1147-58.
275. Shimizu M, Kubota Y, Mason R, Baba J, Calabrese JR, Toichi M: Selective deficit autobiographical incident memory in subjects with bipolar disorder,. *Psychopathology* 2009 Aug 11;42(5):3180324. [Epub ahead of print]
276. Goldberg JF, **Calabrese JR**, Saville BR, Frye MA, Ketter TA, Suppes T, Post RM, Goodwin FK: Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. *J Clin Psychiatry*. 2009 Aug 11. [Epub ahead of print]

In Press Peer-Reviewed Manuscripts

277. Gao K, Verduin ML, Kemp DE, Tolliver B, Ganocy SJ, Elhaj O, Bilali S, Brady K, Findling RL, **Calabrese JR**: Clinical Correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: A subtype comparison. *J Clin Psychiatry*. In Press.
278. Kemp DE, **Calabrese JR**, Quynh-Van T, Pikalov A, Eudicone JM, Baker RA: Metabolic síndrome in patients enrolled in a Clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder. *J Clin Psychiatry*. In Press.

Books, Book Chapters, etc:

279. Avgerinos PC, Schuermeyer TH, Udelsman R, Nieman LK, Gold PW, **Calabrese JR**, Kling MA, Loriaux DL, Chrousos G: Human CRH as a toll for studying the pulsatile function of the hypothalamic-pituitary adrenal axis. In W. Crawl (Ed.) *Episodic Hormone Secretion: Methods of Analysis and Normative Data*. NY, Academic Press, 1985.
280. Gold PW, **Calabrese J**, Kling M, Khan I, Tomai T, Gallucci W, Kalogeras K, Post R, Chrousos G: Clinical studies with CRH: Normal physiology and implications for the pathophysiology of major psychiatric and neuroendocrine disorders. In: *Biological Psychiatry, (Developments in Psychiatry Vol. 7)*, C Shagass, RC Josiassenb, WH Bridger, KJ Weiss, D Stoff, GM Simpson, eds. Amsterdam, Elsevier, 1986, pp 805-807.
281. **Calabrese JR**, Gullede AD, Hahn K, Skwerer RG, Kotz M, Schumacher OP, Gupta MK, Clough JD, Krupp N, Gold PW: Antinuclear antibodies and antithyroid antibodies in psychiatric patients. In: *Viruses, Immunity, and Mental Disease*. E. Kurstak, Z.J. Lipowski, P.V. Morozov (Eds.), Plenum Publishing Co., New York, pp. 353-362, 1987.
282. Gold PW, Kling MA, Kellner CH, **Calabrese JR**, Roy A, Gwirtsman H, Post RM, Pickar D, Avgerinos PC, Loriaux DL, Chrousos G: Corticotropin-releasing hormone: Relevance to normal physiology and to the pathophysiology of depression and anorexia nervosa. In: *Hormones and Depression*. U. Halbreich (Ed.), New York, Raven Press, pp. 77-89, 1987.
283. Gold PW, Kling MA, Khan I, **Calabrese JR**, Kalogeras K, Post RM, Avgerinos PC, Loriaux DL, Chrousos G: Corticotropin-releasing hormone: Relevance to normal physiology and to the patho-

- physiology and differential diagnosis of hypercortisolism and adrenal insufficiency. In: *Hypothalamic Dysfunction in Neuropsychiatric Disorders, Advances in Biochemical Psychopharmacology*, D. Nerozzi, F.K. Goodwin, and E. Costa (Eds.). New York, Raven Press, pp. 183-200, 1987.
284. Gold PW, Kling MA, **Calabrese JR**, Kalogeras K, Avgerinos PC, Loriaux DL, Chrousos G: Physiological, diagnostic, and pathophysiological implications of corticotropin-releasing hormone. In: *Handbook of Clinical Psychoneuroendocrinology*. C.B. Nemeroff, P.T. Loosen (Eds.). New York: The Guilford Press, pp. 85-105, 1987.
285. **Calabrese JR**, Kling MA, Gold PW: Alterations in immunocompetence during stress, bereavement, and depression: Focus on the interplay between the immunologic apparatus and neuroendocrine regulation. In: *Development in Psychoneuroimmunology*. F.H.M. Verhey, H.A.H. D'haenen (Eds). Van Gorcum & Co. Assen/Maastricht, Netherlands, pp. 3-23, 1990.
286. **Calabrese JR**, Wilde C: Alterations in immunocompetence during stress: A medical perspective. In: *Stress and Immunity*. N. Plotnikoff (Ed), Telford Press Caldwell, NJ, 1990.
287. Pycha C, **Calabrese JR**: Good psychosocial adaptation to implantable cardioverter defibrillators. In: *Impact of Cardiac Surgery on the Quality of Life: Neurological and Psychological Aspects*. Ed. Willner A. Plenum Publishers, 1990.
288. **Calabrese JR**: Rapid-cycling manic depression and its treatment. Lapiere, Y.D, (Ed.): In: *Update on the Treatment of Mood Disorders*. Health Care Communications, Inc., Fort Lee, NJ, pp. 9-12, 1990.
289. **Calabrese JR**, Markovitz PJ, Wagner S: Phenomenology of rapid- cycling manic depression and spectrum of efficacy of valproate. In: *Current Practices and Future Developments in the Pharmacotherapy of Mental Disorders*. Eds. H.Y. Meltzer, D. Nerozzi. Elsevier Science Publishers B.V., pp. 149-155, 1991.
290. Bowden CL, **Calabrese JR**, Jamison KR, Keck PE, Swann AC. Bipolar Disorder and Lithium Therapy, 1993. Monograph.
291. *Anticonvulsants in Manic Depression*. Eds. Joffe RT, **Calabrese JR**. Marcel Dekker, Inc., NY, NY, 1994.
292. **Calabrese JR**, Woyshville MJ, Rapport DJ: Clinical Efficacy of Valproate. In: *Anticonvulsants in Manic Depression*. Eds. Joffe RT, Calabrese JR. Marcel Dekker, Inc., NY, NY, 1994, pgs 131-146.
293. Maes M, Calabrese JR: Mechanism of Action of Valproate in Affective Disorders. In: *Anticonvulsants in Manic Depression*. Eds. Joffe RT, **Calabrese JR**. Marcel Dekker, Inc., NY, NY, pp 93-110, 1994.
294. **Calabrese JR**, Bowden CL, Woyshville MJ: Lithium and anticonvulsants in bipolar disorder. In. *Psychopharmacology: The Fourth Generation of Progress*. Eds. F.E. Bloom and D.J. Kupfer. Raven Press, Inc., NY, NY, 1995, pages 1099-1111.
295. Kujawa MJ, **Calabrese JR**: Substance abuse and the treatment of bipolar disorder. In. *Clinical Depression During Addiction Recovery: Process, Diagnosis, and Treatment*. Edited by Jerry S. Kantor. Marcel Dekker, Inc., NY, NY, pp 81-95, 1995.
296. Bauer MS, **Calabrese JC**, Dunner DL, Post R, Whybrow PC, Gyulai L, Younkin S, Bynum D, Lavori

- P: Multi-Site Data Reanalysis: Rapid cycling as a modifier for bipolar disorder in DSM-IV. In: *DSM-IV Sourcebook* Volume 4. Eds: Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis W, Kline M. American Psychiatric Association pgs 125-141, 1998.
297. **Calabrese JR**, Bowden CL, McElroy S, Cookson J, Andersen J, Rhodes L, Woynshville M, Keck P, Kundu S, Paterson G, Ascher J, Bolden-Watson C: Efficacy of lamotrigine in bipolar disorder: Preliminary data. In: *Bipolar Medications: Mechanisms of Action*. Editors: Manji HK, Bowden C, Belmaker R. American Psychiatric Press. 2000, pgs 367-374.
298. **Calabrese JR**, Bowden CL, Woynshville MJ: Lithium and the Anticonvulsants in Bipolar Disorder. In: *Psychopharmacology: The Fourth Generation of Progress*. Bloom FE, Kupfer DJ, eds. CD-ROM Version 3, <http://www.acnp.org/citations/GN401000106>, 2000.
299. Ferrier IN, **Calabrese JR**: Lamotrigine, gabapentin, and the new anticonvulsants: Efficacy in Mood Disorders. In: *Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice*. Eds P.F. Buckley, J.L. Waddington. Butterworth Heinenmann. Pages 190-198, 2000.
300. **Calabrese JR**, Rapport DJ, Findling RL, Shelton MD, Kimmel SE: Rapid-Cycling Bipolar Disorder. In: *Bipolar Disorders. 100 Years After Manic-Depressive Insanity*, Eds: A Marneros, Angst J. Kluwer Academic Publishers. 2000. pgs 89-109.
301. **Calabrese JR**: Introduction. In: *Bipolar Affective Disorders: Etiology and Treatment*. Eds. Joerg Walden, Heinz Grunze. Georg Thieme Verlag, Stuttgart, pages 1-4, 2000.
302. **Calabrese JR**: Bipolar Depression and Rapid Cycling. Monograph published by the Academy for Healthcare Education. July, 2001.
303. **Calabrese JR**, Rapport DJ, Shelton MD: Commentary: Pursuit of the ideal mood stabilizer-Time to give up and move to combination trials. In: *Bipolar Disorder – 5th Vol. World Psychiatric Association Series “Evidence & Experience in Psychiatry*. Eds: M. Maj, H.S. Akiskal, J.J. Lopez-Ibor, N. Sartorius. Publisher: Wiley, Chichester. 2002.
304. Shelton MD, **Calabrese JR**: Lamotrigine: Clinical Efficacy and Use in Psychiatric Disorders. In: *Antiepileptic Drugs Fifth Edition* Eds. Levy RH, Mattson RH, Meldrum BS, Perucca E. Lippincott Williams & Wilkins. Phil., PA. 2002. Pages 403-7.
305. Shelton MD, **Calabrese JR**: Chapter 37 - Lamotrigine. In: American Psychiatric Publishing *Textbook of Psychopharmacology*. Eds. A. Schatzberg, C. Nemeroff, American Psychiatric Publishing, Washington, D.C., 615-626, 2004.
306. Davies MA, Delgado, P, **Calabrese JR**: *Walking on Eggshells: A Resource Book For Families Facing the Challenge of Mental Illness*. 2004.
307. Muzina DJ, Elhaj O, Gajwani P, Gao K, Shelton MD, **Calabrese JR**. Advances in Treatment of Rapid Cycling Bipolar Disorders. In: *Review of Psychiatry, Volume 24. Series Editors: Oldham JM, Riba MB, Treatment of Bipolar Disorder*. Ketter TA (Ed). American Psychiatric Publishing, Inc., April 2005. Pages 147-178.
308. Ketter TA, Sachs GS, Bowden CL, **Calabrese JR**, Chang K, Rasgon NL: Introduction. In: *Review of Psychiatry, Volume 24. Series Editors: Oldham JM, Riba MB, Treatment of Bipolar Disorder*. Ketter

- TA (Ed). American Psychiatric Publishing, Inc., April 2005. Pages 1-10.
309. Muzina DJ, **Calabrese JR**: Chapter 28: Guidelines for Treatment of Bipolar Disorder. In: *Textbook of Mood Disorders*. Eds. Stein DJ, Kupfer DJ, Schatzberg AF, American Psychiatric Publishing, Pages 463-483.
310. Elhaj O, **Calabrese JR**: Rapid-cycling bipolar disorder. In. *Bipolar Disorder: Mixed States, Rapid cycling, and Atypical Forms*. Edited by Andreas Marneros and Frederick K. Goodwin. Cambridge University Press. Pages 61-87. 2005.
311. **Calabrese JR**, Shelton MD, Gao K, Gajwani P, Elhaj O: Lamotrigine. In. *Essentials of Clinical Psychopharmacology*. 2nd Edition. Eds. Alan F., Schatzberg, Charles B. Nemeroff, American Psychiatric Publishing, Washington, D.C. 2006. Pages 403-412.
312. Muzina DJ, **Calabrese JR**: Pharmacological profile and clinical utility of lamotrigine in bipolar disorder. *Bipolar Psychopharmacotherapy: Caring for the Patient*. Edited by Hagop S. Akiskal and Mauricio Tohen, John Wiley & Sons, Ltd. 2006. Pages 43-62.
313. Vieta E, Goikolea JM, Malhi GS, **Calabrese JR**: Eutimizantes (III): Nuevos anticonvulsivantes y antiepilépticos como eutimizantes. In López-Muñoz F, Alamo C, eds., *Historia de la Psicofarmacología*, vol. II. Madrid: Editorial Médica Panamericana, S.A., 2006: 783-794.
314. Muzina DJ, **Calabrese JR**, Bauer M: Lithium in rapid cycling bipolar disorder. In. *Lithium in Neuropsychiatry: The Comprehensive Guide*. Eds. Michael Bauer, Paul Grof, Bruno Muller-Oerlingausen. Taylor & Francis Book Ltd., London, UK. In Press.
315. Kemp DE, Muzina DJ, Gao K, **Calabrese JR**: Antiepileptic drugs in the treatment of rapid cycling bipolar disorder and bipolar depression. In: *Antiepileptic Drugs in Psychiatry*. Editors: Susan L. McElroy, Paul E. Keck, Robert M. Post. In Press.
316. Muzina DJ, Kemp DE, Yatham LN, **Calabrese JR**: Bipolar depression: Diagnosis and Treatment. In. Yatham LN Ed. *Bipolar Disorder: A Clinician's Guide to Biological Treatments*. In Press.
317. Kemp DE, Gao K, Muzina DJ, Gajwani P, **Calabrese JR**: Trial-Based Advances in the Treatment of Bipolar Depression. *Progress in Neurotherapeutics and Neuropsychopharmacology*. Editor: Jeffrey L. Cummings. Cambridge, UK. Cambridge University Press. 2007. Volume 2, pages 193-211.
318. Gao K, Kemp DE, **Calabrese JR**. Pharmacological treatment of the maintenance phase of bipolar depression: focus on relapse prevention studies and the impact of design on generalizability. In: Milestones in Drug Therapy series (M Parnham, J Bruinvels, series eds), *Bipolar Depression: Molecular Neurobiology, Clinical Diagnosis, and Pharmacotherapy*. (CA Zarate Jr, HK Manji, eds). Birkhauser

Verlag AG, Switzerland, Springer Science + Business Media 2009, page 159 – 179.

319. Muzina DJ, Kemp DE, **Calabrese JR**: Mood Stabilizers – Chapter 103. In. Psychiatry 3rd Edition. Editors: Allan Tasman, Kerald Kay, Jeffrey A. Lieberman, Michael B. First, and Mario Maj. Volume 2. Wiley-Blackwell. Pages 2202-2222. 2008.

320. Kemp DE, Muzina DJ, Gao K, **Calabrese JR**: Lamotrigine. In: Textbook of Psychopharmacology (A.F. Schatzberg, CB Nemeroff, Eds. In Press

321. Gajwani P, Muzina DJ, Kemp DE, Gao K, **Calabrese JR**: Update on Quetiapine in the Treatment of Bipolar Disorder: Results from the BOLDER Studies. Neuropsychiatric Disease and Treatment. Neuropsychiatr Dis Treat 2007 Dec;3(6):847-53.

Invited Articles, Non-Peer Reviewed Articles:

322. **Calabrese JR**, Delucchi G: Phenomenology of rapid cycling manic depression and its treatment with valproate. J Clin Psychiatry 1989 Mar;50 Suppl:30-4.

323. **Calabrese JR**, Woyshville MJ: Rapid cycling bipolar disorder: Diagnosis and treatment. Directions in Psychiatry 1994;14:1-8.

324. Rapport DJ, **Calabrese JR**, Clegg K, Ronis RJ: Lamotrigine in treatment refractory major depression. Primary Psychiatry. 1999;6:41-42.

325. **Calabrese JR**: The management of bipolar disorders. Clinician 1999;17:20-25.

326. **Calabrese JR**: Lamotrigine and the treatment of bipolar disorder. Introduction. Eur. Neuropsychopharmacol 1999 Aug; 9 Suppl 4:S107-8.

327. Montgomery S, van Zwieten-Boot B, Angst J, Bowden CL, **Calabrese JR**, Chengappa R, Goodwin G, Lecrubier Y, Licht R, Nolen WA, Sachs G, Saint Raymon J, Strososum P, Suppes JM, van Ree JM: ECNP Nice Consensus Guidelines for Investigating Efficacy in Bipolar Disorder. European Neuropsychopharmacology. 2001;11:79-88.

328. **Calabrese J**: Drug-induced switch rates and their impact in bipolar disorder. European Neuropsychopharmacology. 2001;11 (Supplement 3):S95-S96.

329. Shelton MD, **Calabrese JR**: Lamotrigine use in psychiatry. Primary Psychiatry. 2002 Jan;9(1):50-3.

330. **Calabrese J**: Editorial – Clinical relevance and management of bipolar disorders: Weighing benefits versus risks. Presentations in Focus 2002; 3-4.

331. **Calabrese JR**: Mood stabilization monotherapy is the goal of long-term treatment of bipolar disorder – Pro. J Bipolar Disorders: Reviews & Commentaries. 2003 June II(2):3,16-17.

332. Schneck CD, Allen MH, Shelton, MD, **Calabrese JR**: Current concepts in rapid cycling bipolar disorder. Current Psychosis & Therapeutics Reports. 2004; Sept/Oct 1(2)72-78.

333. **Calabrese JR:** Letter to the Editor of the Cleveland Plain Dealer. Commentary on 'Essay on The Ride from Hell'. Published on October 19, 2003.
334. **Calabrese JR,** Muzina D: How to treat bipolar II depression and bipolar II mixed depression? A reply to Benazzi. *Int. J Neuropsychopharmacology.* 2004 Mar;7(1-2).
335. Hirschfeld RM, Wagner KD, Holzer C, **Calabrese JR,** Davies MA, Weissman MM, Reed MA, Keck PE, McElroy SL, Lewis L, McNulty J: Response to commentary: "using questionnaires to screen for psychiatric disorders". *J Clin Psychiatry* 2004 May;65(5):721-2.
336. **Calabrese JR,** Keck PE, Bowden CL, Ketter TA, Sachs G, Findling RL, Sajatovic M: A US perspective of the 2005 Canadian Guidelines of Bipolar Disorder. *Bipolar Disorders.* 2005 June;7 (Suppl.3):70-72.
337. Yatham L, Goldstein J, Vieta E, Bowden CL, Grunze H, Post R, Suppes T, **Calabrese JR:** Atypical antipsychotics in bipolar depression: Potential mechanisms of action. *J Clin Psychiatry* 2005 May;66[Suppl 5]:40-48.
338. **Calabrese JR,** Elhaj O, Gajwani P, Gao K: Clinical highlights in bipolar depression: Focus on Atypical Antipsychotics. *J Clin Psychiatry* 2005 May;66[Suppl 5]:26-33.
339. **Calabrese JR:** *Invited Guest Editor - Commentary:* One-year outcome with Antidepressant treatment of bipolar depression – Is the glass half empty or half full? *Acta Psychiatr. Scand.* 2005 Aug;112(2):85-87.
340. Mehta A, **Calabrese JR:** Rapid cycling bipolar disorder: Update on phenomenology and treatment. *Medscape Psychiatry & Mental Health.* 2005;10(2).
341. Youngstrom EA, Youngstrom, JK, **Calabrese JR:** Screening for bipolarity: A brief review of available measures and recommendations for future research. *Aspects of Affect.* 2005 Dec;1(2)85-91.
342. Muzina DJ, Gajwani P, Kemp DE, Gao K, **Calabrese JR:** Anti-epileptic drugs for acute bipolar depression: Applying data to clinical practice. *Psychiatric Annals.* 2006;36(9):637-644.
343. Gao K, Gajwani P, Muzina D, Abraham PF, Xia G, **Calabrese JR:** The effects of antipsychotics on mood. *Advances in Schizophrenia and Clinical Psychiatry* 2006;2:120-127.
344. **Calabrese JR,** Muzina D, Kemp DE, Sachs GS, Thompson TR, Klingman D, Reed ML, Hirschfeld RMA: Predictors of bipolar risk among patients currently treated for major depression. *MedGenMed.* 2006 Aug 15;;8(3):38.
345. Abraham P, **Calabrese JR:** Book Review of *Lithium Treatment of Mood Disorders: A Practical Guide. Bipolar Disorders.* 2007;9(5):548.